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COVER: 
Saint Agatha (Catania, Italy, 3rd century A.D.) was treated cruelly by the Roman 
governor of the island of Sicily because she would not accept his lustful designs 
and, on the pretext of the persecution of Christians, he ordered that she should 
be bound to a stake and her breasts removed. In the Western Church Saint 
Agatha is regarded as the patron saint of diseases of the breast. 
On this picture Saint Agatha holds her attribute, a severed breast, with iron 
pincers. She stands against a dark crimson textile on which is represented a 
repeated motif in gold of a phoenix rising in flames toward a burning sun. This 
motif is appropriate to Agatha, also known as the fire maiden, through her as-
sociation with voléanos and lava and her patronage of forging and casting. 
Reference to this patronage is to be found in the border: in her monograms 
wrought of gold, in the gold and enamel jewelry, and in gift-wrapped boxes of 
jewels. Also in the border are careful imitations of various kinds of weaving. 
(Source: Het Getijdenboek van Catharina van Kleef. Uitgeverij Meulenhoff, 
Amsterdam, 2e druk, 1975). 
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GENERAL INTRODUCTION 
1 
GENERAL INTRODUCTION 
Cancer of the female breast is a major public health 
problem m The Netherlands (total female population in 1982: 
7.221.000), affecting one out of twelve women in the course 
of their lives. Annually about 6800 cases are newly detected 
and at the same time 2893 patients died of the disease in 1982 
(1,2). Thus the mortality rate is approximately 40% and this 
figure has remained almost constant over the past thirty years 
(3,4). A slight increase in survival may be attributed to the 
earlier clinical stage in which patients nowadays present 
themselves for treatment. Different treatment modalities all 
aimed at locoregional tumour control have little or no 
influence on long-term survival given a certain stage of the 
tumour (T.-T.). Therefore, all hope to improve prognosis of 
mammary carcinoma is focused on earlier detection, i.e. in 
its pre-clinical or nonpalpable stage (Tn). 
Various diagnostic methods have their inherent limitations 
or disadvantages: 
- Transillumination is now largely of historical interest (5). 
- Infrared thermography, although cheap and noninvasive, has 
a relatively low sensitivity and specificity for the 
detection of occult carcinomas (6,7). 
- Ultrasound examination is usually not appropriate for solid 
lesions with a diameter of 10 mm or less and for micro-
calcifications (8). 
- Computerized tomography of the breast using body CT machines 
requires a high dose of intravenous lodinated contrast 
material, is a lengthy procedure and extraordinarily 
expensive (9,10). 
- Arteriography with lodinated contrast material requires 
selective cannulation of the subclavian or internal mammary 
artery and is time-consuming; the radiation dose is high and 
only large lesions over 1.5 cm in diameter were examined (11). 
- Digital subtraction angiography (DSA) of the breast has the 
same disadvantage: venous catheterization into the superior 
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vena cava, a total radiation exposure of approximately 2 cGy 
for each DSA study and relatively expensive, mainly because 
of the duration of the examination of approximately one hour 
(12) . 
- Galactography is only to be used in case of nipple discharge 
(13). 
- Breast scintigraphy with 99 m Tc-diethylene triamine penta-
acetic acid is able to differentiate between benign and 
malignant tumours, but in view of the low sensitivity its 
diagnostic value is limited (14). 
- Nuclear magnetic resonance imaging as a tool in the diagnosis 
of breast disease is still in its experimental stage and its 
merit has to be confirmed through large-scale clinical 
studies (15,16). 
Mammography has proven to be most apt to visualize 
mammary carcinoma even in its nonpalpable stage with nowadays 
a sensitivity of up to 95% (17,18). The fear of cancer 
induction through repeat mammographies (19) might have been 
true in the early days of conventional mammography or xero-
radiography in the sixties, but is totally unwarranted since 
the development of the dedicated mammography unit with a 
molybdenum target tube and filter, the introduction of screen-
film combinations, compression devices and small focal spots 
(20). These technical improvements have caused that the average 
mid-breast radiation dose does not exceed 1 mGy per image (21). 
As a result of this it has been extrapolated that the average 
excess risk of breast cancer induction by mammographie screening 
is 0.042% per mGy (22), which is negligible in view of the 
anticipated possible benefits. 
Despite some persistent pessimism (23), there is now 
increasing evidence that mammography is able to reduce 
mortality from breast cancer by earlier detection: 
- First of all the much quoted randomized study of the Health 
Insurance Plan of Greater New York (HIP), which started 
already in 1963, using physical examination (palpation) and 
conventional mammography as screening tests, has shown after 
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14 years a 30% reduction in mortality rate in women offered 
screening, initially only in the age group over 50, but later 
also in women aged 40-49 years (24). 
- The second controlled trial, randomized on community level, 
started in 1977 and was carried out in Kopparberg and Öster-
götland, Sweden. Here the only screening modality was single 
mediolateral oblique view mammography (25). After seven 
years of follow-up a 31% reduction in mortality from breast 
cancer was observed (26) . 
- The last two population-based studies, which have been 
evaluated so far, are non-randomized, but have a case 
referent design. In the Utrecht study, started in 1974, xero-
mammography plus physical examination were used as screening 
modality involving women between 40-64 years. After four 
screening rounds or six years of follow-up mortality from 
breast cancer was reduced 70% in screened versus unscreened 
women (27) . 
- The Nijmegen study, using modern mammography only with a 
single oblique view, started in 1975 and was aimed at all 
women over 35 years of age. The results after four rounds of 
screening showed a 52% reduction in mortality amongst screened 
subjects (28). In this study no benefit of screening in 
respect of relative risk of dying from breast cancer could 
be demonstrated in the youngest age group (35-49 at entry) 
(29) . 
- More breast cancer screening projects are under way in the 
United States (30,31), Canada (32), United Kingdom (33,34) 
and Sweden (3 5,36) . 
Although the above vital statistics are of utmost importance 
for the population m general, the practising clinician m 
particular might wish to know more details regarding the 
individual patient with clinically occult or nonpalpable 
breast carcinoma. This thesis tries to elucidate some of these 
aspects from a surgeon's point of view. 
- Chapter I deals with the problem how to remove a nonpalpable, 
yet mammographically suspicious breast lesion. Three methods 
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of localization and excision are evaluated. The efficacy is 
assessed in respect of number and size of the biopsies. It is 
not only important for malignancies that the correct piece 
is removed for pathological examination, but also for benign 
biopsies that this is carried out with the least possible loss 
of volume. The failure rate is investigated and the results 
of repeated biopsies are presented. 
- In Chapter II the clinical significance of pure micro-
calcifications without palpable mass in a large series of 
patients is examined: the reasons for mammography, the age 
distribution, the yield of malignancies, the histological 
types and the axillary status. The appearance of the micro-
calcifications is discussed and an overview of the 
literature is given. 
- Various mammographic-histopathologic correlations of non-
palpable breast lesions are studied in Chapter III and the 
respective yields of invasive and noninvasive carcinomas are 
presented. The feasibility of the frozen section examination 
is investigated and its consequences for treatment policy are 
discussed. 
- In Chapter IV the results of oestrogen and progesterone 
receptor studies in nonpalpable breast cancers are documented. 
The receptor phenotypes are compared between nonpalpable 
primary breast cancer, palpable primary breast cancer, loco-
regionally advanced primary breast cancer and first metastatic 
breast cancer. Its significance for tumour biology is 
considered. 
- Chapter V deals with multicentricity (invasive or noninvasive 
carcinoma outside the quadrant of the reference tumour) and 
residual tumour (invasive or noninvasive carcinoma outside 
the excisional biopsy cavity) in nonpalpable breast carcinoma. 
This is especially important in view of the modern trend of 
breast conserving surgery for small carcinomas. 
- The role of mammography in the detection of contralateral 
primary breast cancer is evaluated in Chapter VI. Non-
palpable breast cancers are studied in synchronous and 
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metachronous bilateral breast disease in respect of multi-
centricity and axillary status. Failure to discover meta-
chronous second primary breast cancer in its nonpalpable 
stage is analysed. The 5- and 10-year survival rates of 
bilateral primary breast cancer are presented. 
- In Chapter VII treatment and long-term survival results of 
nonpalpable breast cancers are demonstrated and analysed 
according to invasive tumour size (upper limit at 5 or 10 
mm) or axillary status (positive versus negative nodes). 
The concept of minimal breast cancer is reconsidered in 
light of the present figures. 
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Chapter I 
LOCALIZATION AND EXCISION OF NONPALPABLE BREAST 
LESIONS; A SURGICAL EVALUATION OF THREE METHODS 
J.G.M. Tinnemans, Th. Wobbes, J.H.C.L. Hendriks, 
R.F. van der Sluis, E.J.C. Lubbers, H.H.M, de Boer 
Arch Surg, accepted for publication 
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1.1 INTRODUCTION 
With the increased use of mammography, especially in breast 
screening programs, more and more suspect but nonpalpable 
breast lesions are being detected which require excisional 
biopsy for histological diagnosis. The management of these 
clinically occult lesions poses a challenge to the surgeon 
who is requested to remove the correct piece of breast tissue 
with the least possible harm. The latter is particularly 
important in case the radiographic lesion turns out to be 
benign. 
Several preoperative localization techniques have been 
described to guide the surgeon during biopsy. Most authors 
claim improved accuracy of the biopsy with their method of 
localization, but little or no proof of this has been given. 
Only a few evaluations have been published so far, but data 
comparing different methods of localization are even more 
scarce (1-4). 
1.2 PATIENTS AND METHODS 
Between January 1, 1975, and December 31, 1983, 300 
consecutive women underwent breast biopsies because of non-
palpable, radiographically suspicious findings. All patients 
were treated in the St. Radboud University Hospital, Nijmegen, 
The Netherlands. Out of 335 biopsies, 101 clinically occult 
breast cancers (invasive and non-invasive ductal carcinoma) 
have been encountered in 96 patients. 
From 1975 until mid 1977, we performed 'blind' biopsies 
by measuring the distances in two projections (craniocaudal 
and lateral) using the nipple as a reference point. Since mid 
1977 we started using a preoperative needle localization 
technique with a flexible self-retaining barbed guide wire (5). 
The insertion of the wire was aided by a multiperforated 
compression plate, as described below, since January 1982 (6,7). 
Localization: Before the scheduled operation, the patient is 
taken to the mammography unit of the radiology department, 
which is equipped with a Senographe 500 Τ (CGR). The usual 
compression plate is replaced by a home-made multiperforated 
plexiglas compression plate, which is placed over the breast. 
A craniocaudal view is taken and the film is developed 
while the breast remains compressed. After identifying the 
hole overlying the radiographically suspicious lesion, a 
commercially available localization needle containing a 
flexible hooked guide wire (Cook) is introduced into the 
breast through the appropriate hole. The needle is inserted 
perpendicular to the compression plate and advanced to the 
desired depth as determined earlier on the lateral view of 
the compressed breast. Thereafter, the needle is withdrawn, 
leaving the barbed wire anchored in the breast parenchyma in 
close proximity to the radiographical lesion. Postlocalization 
mammograms in the two projections are obtained to document 
the position of the wire tip relative to the lesion. Because 
of its self-retaining nature,the guide wire does not need to 
be taped to the skin. The skin area and the exposed guide 
are covered with a sterile dressing while transfer to 
surgery is being awaited. 
Operation: Biopsy is performed under general anaesthesia 
using a transverse skin incision, but for subareolar lesions, 
a semi-circumareolar incision may be preferred. The surgeon 
searches for the wire subcutaneously. After exposure of the 
guide in the wound, the wire is followed to the calculated 
depth and a piece of mammary tissue, including the wire tip, 
is excised en bloc. Radiography of the excised specimen is 
mandatory in order to confirm that the mammographie lesion 
has actually been removed and also to direct histological 
examination. 
During this 9-year period, one of us (JHCLH) performed 
or supervised all localization procedures, but the biopsies 
were performed by various surgical residents, usually super­
vised by members of the surgical staff. 
All case-sheets and operation reports were studied 
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Table 1: Comparison of two methods of preoperative needle localization of nonpalpable 
mammographie lesions 
Total Distance Distance of the wire tip relative to the lesion 
known 0 ^-1 cm 1^ -2 cm 2^-3 cm 3^-4 cm 4^ -5 cm 
Needle localization N 
% 
163 131 
100 
28 62 
21.4 47.3 
22 
16.8 
11 
8.4 
5 
3.8 
3 
2.3 
Needle localization 
with multiperforated N 
compression plate % 
62 55 
100 
27 
49.1 
17 
30.9 
7 
12.7 
4 
7.3 
retrospectively in regard to the following items: the distance 
between the tip of the wire and the mammographie lesion, the 
adequacy of removal of the nonpalpable lesion by x-ray 
confirmation (specimen radiography or postoperative repeated 
mammography) and the number and size of the biopsies. Failures 
and complications were noted. 
1.3 RESULTS 
Preoperative needle localization was highly successful 
right into or transfixing the mammographie abnormality in 
21.4% of the patients without the perforated compression plate, 
increasing to 49.1% in the group with the perforated compression 
plate (Table 1). The localization procedure was considered to 
be unsatisfactory if the distance of the wire tip relative to 
Table 2: Accuracy of excision of 335 nonpalpable mammographie 
lesions 
Histological 
X-ray confirmation 
Total confirmation only Failure 
Mastectomy 
Blind biopsy 
N 
% 
N 
% 
3 
100 
107 
100 
100 
93.4 
3 
100 
5 
4.7 
2 
1.9 
Biopsy after needle N 163 146 
localization % 100 89.6 
13 
8.0 
4 
2.4 
Biopsy after needle N 62 
localization with % 100 
multi-perforated 
compression-plate 
56 
90.3 
5 
8.1 
1 
1.6 
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Table 3: Analysis of failures of excision of nonpalpable 
mammographie lesions 
patient Age Mammographie 
abnormality 
Method of 
localization 
Specimen 
x-ray 
A 
В 
С 
D 
E 
F 
50 
55 
19 
52 
58 
47 
68 
spiculated opacity blind 
circular opacity blind 
microcalc. 
microcalc. 
microcalc. 
microcalc. 
microcalc. 
3x neg. 
4x neg. 
2x neg. 
3x neg. 
2x neg. 
needle (tip at 1 cm) 
needle (tip at 1 cm) 
needle (tip at 1 cm) 
needle (tip at 21¡ cm) 4x: 
lx pos.? 
3x neg. 
needle through 3x neg. 
perforated 
compression plate 
(tip at 2 cm) 
Patient Repeat Follow-up 
mammography 
F 
G 
after 5 months 
repeated biopsy 
(quadrant excision) 
after % month 
repeated biopsy 
because of young age 
no further action 
taken; probably of 
traumatic origin 
after 3 months 
repeated biopsy 
after 25 months 
repeated biopsy 
after 7 months 
repeated biopsy 
after i month 
repeated biopsy 
Final 
histopathology 
small invasive ductal 
carcinoma with nega-
tive axillary nodes 
invasive ductal 
carcinoma 0 10 cm 
with negative 
axillary nodes 
normal mammary 
tissue with fibrosis 
proliferative fibro-
cystic disease with 
atypia 
multifocal in situ 
ductal carcinoma with 
negative axillary nodes 
simple fibrocystic 
disease 
simple fibrocystic 
disease 
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the breast lesion was greater than 2 cm, which was the case in 
14.5% without the perforated compression plate and in 7.3% with 
the aid of the perforated compression plate. In the latter 
group the distance never exceeded 3 cm, while in the former 
group poor localization occurred in 6.1%. 
As can be seen in Table 2, the great majority in each of 
the three groups had x-ray confirmation, mainly by specimen 
radiography, but in 8 patients proof that the suspicious lesion 
had been removed was given by repeated mammography, 
Primary subcutaneous mastectomy with immediate prosthetic 
implant was performed in three patients and consequently x-ray 
confirmation of the removed breast was considered to be 
superfluous. All three had in situ ductal carcinoma. 
Of 23 others,no x-ray confirmation was carried out or 
could be retrieved from the records, but it was most likely,on 
histological grounds,that the mammographie abnormality had 
been removed: 13 cases of malignancy, 6 cysts,and 4 cases of 
microcalcifications. 
True failures were encountered in 7/332 = 2.1%. A detailed 
analysis is presented in Table 3. Repeated biopsies in six 
patients revealed three malignancies: 2 infiltrating ductal 
carcinomas and 1 in situ ductal carcinoma. 
Table 4 shows the efficacy with which the impalpable 
mammographie lesions have been removed. Four out of five 
biopsies were successful at first attempt with any method, 
but there is a tendency that fourth and fifth attempts 
occurred a bit more often if no needle localization was used. 
The average size of the biopsies decreased from 93.4 cm 
without needle localization to 68.1 cm when localized with 
a wire through the perforated compression plate. The difference, 
however, did not reach statistical significance (Table 5). 
Difficulties with specimen radiography were encountered 
twice: both patients had blind biopsies because of micro-
calcifications. After the fourth attempt,the operations were 
terminated, but the radiologist reported afterwards that the 
suspicious lesions had been removed yet on the first attempt! 
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Table 4: Comparison of three methods of excision of nonpalpable breast lesions: 
number of biopsies 
Total Number of biopsies 
1 2 3 4 5 
Blind biopsy N 107 84 
% 100 78.5 
Biopsy after N 163 131 
needle localization % 100 80.4 
Biopsy after needle N 62 49 
localization with % 100 79.0 
multiperforated 
compression plate 
10 
9 . 3 
22 
13.5 
8 
12.9 
6 
5 .6 
9 
5 . 5 
4 
6 . 5 
5 
4 . 7 
1 
0 . 6 
1 
1.6 
2 
1.9 
о 
Table 5: Comparison of three methods of excision of nonpalpable breast lesions: 
size of biopsies 
Total Number Median _ Ilean - Range 
number size known size (cm ) size (cm ) (cm·^ ) 
Blind biopsy 107 63 62 93.4 2 - 420 
Biopsy after 
needle localization 163 118 61 82.6 3 - 476 
Biopsy after needle 
localization with 
multiperforated 
compression plate 62 30 71.5 68.1 4 - 180 
ρ > 0.30 (Kruskal-Wallis test) 
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Complications of wire placement were seen in four 
instances. Two guide wires broke off, but the mammographie 
lesions,including the broken wires,have been removed on the 
first and second attempt respectively. Intra-operative wire 
dislodgement occurred once, yet the first biopsy was success-
ful. In one case the guide was inadvertently introduced 
below the fascia of the underlying pectoralis musculature, 
but this was recognized in time with successful removal on 
the initial biopsy attempt. 
1.4 DISCUSSION 
A variety of methods to aid in localizing mammographie 
nonpalpable lesions prior to surgery has been developed and 
they may be grouped into non-mvasive and invasive techniques. 
Non-invasive techniques employ geometrical coordinates, 
using the nipple as reference point either plotted on a diagram 
(4,8,9) or visibly marked on the skin (10). Others used stereo-
mammograms (11) or visual and radiopaque external skin markers 
(12,13). Although this method may be suitable for lesions 
located superficially or adjacent to the nipple, in general, 
the technique lacks precision when dealing with deep lesions, 
especially in voluminous and pendulous breasts. This is caused 
by the difference in shape and position between the sitting 
posture during compression mammography and the surgical 
supine position. As a result of this,usually generous biopsies 
are obtained or segmentectomies (4,10,14) performed. In order 
to minimize the size of the excised specimen, several invasive 
techniques using internal markers have been advocated. 
The percutaneous placement of single or multiple hypo-
dermic or spinal needles have been described (1,15,16,17,18).The 
point of insertion of the needle(s) may be calculated according 
to the linear or the arc method (19,20). Needle placement may 
be facilitated by the use of a perforated grid compression 
device (6) or a stereotaxic instrument (21). Needles inserted 
perpendicular to the skin have the chance of accidentally 
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perforating the pleural cavity and one case of transgression 
into the chest has been reported (22). By placing the needle 
parallel to the chest wall this risk is reduced (23) . The 
indwelling straight needles are usually introduced to its hub 
and taped to the skin. However, tape may come off if wet, 
during transport or surgical preparation, and a modified 
needle has been described which can be sutured to the skin to 
prevent dislodgement (24). The drawback of the fixation to 
the skin of any straight needle is that with compression the 
needle may be driven farther into the breast. 
A way of overcoming the problem of needle motion and 
subsequent displacement is the spot method which consists of 
injecting a mixture of radiopaque and visible dye (25,26,27, 
28). A water-soluble contrast medium is preferable, because 
oily contrast agents may obscure the visualization of the tiny 
microcalcifications on specimen radiograms and, if not removed, 
may cause foreign body granulomas (25,26). The visible dye, 
methylene blue or Evans blue,serves as an internal surgical 
landmark (25,27,28,29). Because of gradual diffusion into the 
surrounding breast parenchyma,biopsy should follow within four 
hours of injecting the localizing visible dye (27). When blue 
dye enters mammary ducts,it may result m rapid dispersion, 
blurring the original spot. 
Spherical marking is a different method, which is 
independent from the localization/operation interval. Through 
a wide bore needle,radiopaque internal markers are introduced 
like platinum coated gold grains (30) or small stainless steel 
balls (31). The disadvantage of this method is that proof of an 
appropriate biopsy and retrieval of the internal markers will 
not be seen by the surgeon until specimen radiography has been 
performed. 
The needle localization technique has essentially been 
improved by the introduction of the Frank needle, a flexible 
guide wire which can firmly be anchored m the breast tissue 
by its barbed end (5). This method has gained widespread 
popularity (2,32-37) and some minor modifications have been 
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described (38-42). 
Accuracy in positioning of the marking wire may be 
increased by the perforated plexiglass compression plate and 
a combination of the Frank needle and the Mühlow localization 
technique (18) has been reported from Scandinavia (3,7,43,44). 
In order to ensure the introduction of the needle in the 
correct perpendicular direction, a special aiming device has 
been constructed, which can be placed on the compression plate 
over the appropriate hole (43). 
Correct excision of the occult breast lesion on the first 
attempt has been reported between 78% and 100% in small series 
(2,3,31,34). Using the Frank needle for localization, Chetty 
et al (36) performed accurate excision at first attempt in 
62 of 80 mammographie abnormalities (=78%). Rosen and Snyder 
(45) reported successful initial biopsies in 90 out of 98 non-
palpable breast lesions (=92%), but the biopsies guided by 
preoperative mammography only were usually 'generous'. Powell 
et al (4) demonstrated that more than one biopsy was required 
in 33 out of 200 segmentectomies (=17%), decreasing to 4 out 
of 82 (=5%) when dye contrast injection was done prior to 
segmentectomy. However, the size of the segments removed was 
not indicated, but was said to be large. 
Only a few authors mention the size of the biopsies. 
Taking generous blind biopsies in 52 patients because of 
clustered microcalcifications Roses et al (14) found an average 
maximal diameter of the specimens removed of 6.4 cm. Hoehn 
and co-workers (33,35), using the Frank needle, reported a mean 
volume of the excised tissue of 82.4 cm , diminishing with 
increasing experience to 67.9 cm , approximately a cube of 
4.1 cm on each side. 
In our series, about 80% of the occult mammary lesions were 
removed at first attempt with any method of localization. 
However, the size of the biopsies seemingly decreased, but did 
not differ significantly between the three groups studied. The 
lack of significance is caused by the wide range of the biopsy 
specimen volumes and this rather reflects the large biopsy specimens. 
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for deep-sited lesions in large-breasted women. 
Failure to remove the mairmographically suspicious area 
during the initial operation,despite multiple biopsies,has 
been reported to be from 1.6% to 8.8% (1,2,35,36,43-46). 
Lack of communication between surgeon, radiologist,and 
pathologist has been considered a major potential cause of 
failure (1). 
Our failure rate of 2.1% in a large series of 332 biopsies 
for occult breast lesions compares favourably with the above-
mentioned figures. Furthermore, since three of the six repeated 
biopsies in our material yielded malignancy, the persistent 
presence of a radiographically suspect lesion on the post-
operative mammogram is an urgent indication for re-operation. 
1.5 SUMMARY 
Three methods of excising nonpalpable breast lesions have 
been evaluated: 1. 'Blind' method using mammographie coordinates. 
2. Preoperative localization with the Frank needle. 3. Frank 
needle localization aided by a multiperforated compression 
plate. Successful removal at first attempt occurred in about 
80% with any method. The size of the biopsies did not differ 
significantly between the three groups and is most probably a 
function of the breast volume. The failure rate was seven out of 
332 biopsies (2.1%). Since three of the six repeated biopsies 
yielded malignancy,the persistence of a radiographically 
suspicious lesion on follow-up mammogram of the operated breast 
is an urgent indication for re-operation. 
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11.1 INTRODUCTION 
During the past two decades, mammography has been 
established as an indispensable addition to complete 
evaluation of symptomatic women and as a valuable screening 
method to detect early breast cancer in asymptomatic adults. 
The surgeon is increasingly asked to remove clinically 
occult breast lesions to obtain a histologic diagnosis. The 
smallest among these nonpalpable mammographie lesions are the 
microcalcifications without an associated mass. 
This article presents our experiences as viewed by the 
clinician in excising these clinically occult microcalcifi-
cations and discusses its significance in relation to breast 
carcinoma. 
11.2 PATIENTS AND METHODS 
The data of 150 consecutive female patients with non-
palpable clusters of microcalcifications without an 
associated mass treated between January 1, 1975, and 
December 31, 1983, at the St. Radboud University Hospital in 
Nijmegen, The Netherlands, formed the basis of our study. 
Eighty-five women were completely asymptomatic and 
detected by a single-view, mammographie, population-screening 
program conducted within the city of Nijmegen aimed at the entire 
female population older than 3 5 years of age (1). The 
remaining 65 patients attended because of breast complaints, 
but had no palpable mass associated with the radiographic 
calcifications. 
Table 1 shows the reasons for mammography. The vast 
majority are women without symptoms found by population 
screening (52.5%). In 34 patients (21%) breast complaints, 
mainly mastodynia, were an indication for mammography. The 
others were patients with an increased risk, of developing a 
breast malignancy and were under periodic mammographie 
checkup because of a known premalignant lesion such as 
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Table 1: Reasons for mammography m 162 operations 
Population screening 
Mastodynia 
Control 'premalignant lesion' 
Mastectomy of contralateral breast 
Other reasons 
Carcinophobia 
Positive family history 
No. of 
patients 
85 
34 
18 
10 
9 
5 
1 
% 
52.5 
21.0 
11.1 
6.2 
5.6 
3.1 
0.6 
atypia (11.1%) or had a mastectomy of the contralateral 
breast in the past (6.2%). 
Each woman received routine mammographie examination 
that consisted of craniocaudal and lateromedial views, ilammo-
graphy was carried out with a molybdenum anode and a 0.3 mm 
focus. If necessary, small details could be visualized more 
accurately by microfocal spot magnification with a 0.1 mm 
focus. 
The sole indication for biopsy was an isolated group of 
five or more microcalcifications per square centimeter. Tnus 
a total of 173 groups of microcalcifications were excised and 
studied. 
In 1977 a preoperative needle localization technique 
was introduced that used a flexible, self-retaining, hooked 
guide wire (2). Before then we performed 'blind' biopsies by 
calculating the three-dimensional distances on the mammogram. 
In the past few years, insertion of the wire was aided by a 
multiperforated plexiglass compression plate that was placed 
over the breast for the mammogram (3). The needle containing 
the wire could be inserted through the appropriate hole to 
the desired depth. The exact position of the wire tip was 
checked radiographically. 
All operations have been performed under general 
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anesthetic. The surgeon then excised the area around the wire 
hook, and the specimen was always radiographed. After 
confirmation that the excised tissue contained the mammo-
graphie microcalcifications concerned, the specimen was sent 
to the pathologist who cut the tissue in slices, and these 
slices, arranged in proper order, were again radiographed. 
Sometimes, frozen section was possible, but often the 
definitive diagnosis had to be deferred until the paraffin 
sections were ready (4). 
II.3 RESULTS 
The 173 biopsies in 150 patients for multiple 
calcifications only were 13% of the total of 1329 breast 
biopsies performed on inpatients during this 9-year period. 
Table 2: Histologic diagnosis of nonpalpable radiographic 
microcalcifications 
No. % 
Benign lesions 
Simple fibrocystic disease 
Mastopathy with atypia 
Papillomatosis 
Fibroadenoma 
Hyperestrogenic effects 
Normal mammary tissue 
Malignant lesions 
Invasive ductal carcinoma 
Invasive lobular carcinoma 
DCIS 
LCIS 
Basal cell epithelioma 
Including one patient with Paget's disease 
122 
63 
31 
18 
6 
1 
1 
51 
19* 
2 
22 
7 
1 
100 
51.6 
25.4 
14.8 
6.6 
0.8 
0.8 
100 
37.3 
3.9 
43.1 
13.7 
2.0 
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In 20 patients, more than one group of microcalcifications 
had been excised: 17 patients had two clusters, and 3 patients 
had three clusters of microcalcifications removed. 
In 11 patients two clusters of x-ray film calcifications 
had been removed within one operation: five times from the 
same breast and six times from both breasts. Thus 162 
operations were required to have the 173 mammographie lesions 
removed. 
The left to right ratio was 1.40 : 1.00. Most x-ray-
film calcifications were located in the upper outer quadrants 
of the breasts (41.6%) or centrally behind the nipple (22%). 
The lower inner quadrants were a less frequent site (8.7%). 
As shown in Table 2 benign breast lesions were noted 
in 122 biopsies, or 70.5% of the total group. 
In 63 cases it comprised simple fibrocystic disease 
without epithelial proliferation. Papillomatosis and the 
presence of atypical ductal or lobular hyperplasia were 
encountered 49 times (40.2% of all benign biopsies). 
Table 2 also shows the distribution of the malignancies. 
Fifty-one malignant lesions (29.5% of all biopsies) were 
found in 47 patients (31.3% of all patients). Four patients 
had two malignancies: one patient was found to have a ductal 
carcinoma with early invasion at two different places of the 
same breast. Another patient with lobular carcinoma in situ 
(LCIS) was kept under regular physical and radiographic 
control; three years later she had microcalcifications in 
another quadrant of the same breast that again proved to be 
LCIS. 
Two patients had bilateral nonpalpable malignancies: 
one patient with ductal carcinoma in situ (DCIS) in both 
breasts and one patient with an invasive ductal carcinoma on 
one side and a LCIS on the other side. 
DCIS was seen most frequently (22 cases, or 43.1% of all 
malignancies). If LCIS is included, all 29 noninvasive 
cancers account for 56.8 of the malignant biopsies. 
Invasive ductal carcinoma was encountered 19 times 
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Figure 1 : Age distribution of patients with microcalcifications 
and relationship with pathologic findings 
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(37.3% of the malignancies); invasive lobular carcinoma was 
the least frequent cancer and was seen in only two cases (3.9%). 
In Figure 1 the age distribution of the patients at the 
time of the 162 operations is given. The mean age was 50.2 
years (range 19 to 73 years). 
Breast cancer has not been found in any of the 17 patients 
under the age of 40 years who had a biopsy for nonpalpable 
microcalcifications. 
From 1975 to 1977, the treatment policy at the St. Radboud 
University Hospital for invasive carcinoma and DCIS consisted 
of radical mastectomy for lateral tumors and simple mastectomy 
followed by irradiation of the regional lymph nodes for medial 
and central tumors. Since 1977 the primary surgical treatment 
has shifted toward modified radical mastectomy, including 
an infraclavicular apical biopsy. 
Thus only 14 patients with nonpalpable invasive breast 
cancer and 13 patients with nonpalpable DCIS had a fully 
évaluable axillary status. In three cases (11.1%) there were 
regional or distant metastases (Table 3). 
One patient with an invasive ductal carcinoma with a 
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Table 3: Axillary status of nonpalpable radiographic micro-
calcifications 
Evaluable Positive 
axillary lymph 
No. lymph nodes nodes 
Invasive carcinoma 20 14 3 
Noninvasive carcinoma 
DCIS 22 13 0 
LCIS 7 0 0 
Including one patient with distant metastases 
pathologic diameter of 30 mm had three positive lymph nodes 
of 25 axillary nodes found: one minimal localization at level 
3 and two with extranodal localizations at level 2. 
The second patient had an invasive lobular carcinoma 
with a pathologic size of 80 mm, and four of 34 nodes 
contained secondary tumors: two at level 3 and two at the 
interpectoral level. 
The third patient was first discovered because of a 
pathologic fracture of the sternum. There were no palpable 
findings in the breasts or the axillae. Mammography disclosed 
a group of microcalcifications in a typical triangular 
configuration, and at biopsy an invasive ductal carcinoma 
was found. Results of both sternal and crista biopsies 
showed the same type of cancer cells. 
II.4 DISCUSSION 
Although Albert Salomon (5), a surgeon in Berlin, 
discovered in 1913 that x-ray film calcifications are 
associated with breast cancer, it was not until the 1930s 
that the first reports appeared on the clinical use of 
mammography (6,7). After Raul Leborgne (8), a radiologist 
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in Montevideo, described in 1951 a radiologic technique that 
made it possible to visualize tiny microcalcifications, 
modern mammography has developed further in the past decades 
by the introduction of the molybdenum anode, the so-called 
low-dose screen-film combination, and recently by the use of 
0.1 mm microfocus, which allows focal spot magnification of 
1.5 to 2 times. 
Microcalcifications contain calcium hydroxyapatite or 
tricalcium phosphate (9,10) and are considered a secretion 
product of increased cellular activity in the lobuloductal 
complex (11) rather than the result of mineralization of 
necrotic cellular debris. 
The appearance of the microcalcifications varies in size, 
shape, density, number, and distribution, and accordingly the 
level of suspicion of malignancy may increase or decrease. 
For example, very fine calcifications that vary greatly in 
form (polymorphism) are considered a clue to the presence 
of carcinomas (12). On the other hand, coarse-plaqued 
calcifications that appear on the lateral film as sickle- or 
linear-shaped configurations are regarded as typical 'tea-cups' 
corresponding with benign microcysts filled with calcium milk 
(13). A marked increase in the number of microcalcifications 
compared with previous examinations favors the diagnosis of 
malignancy (14). On the basis of the anatomy of the lactiferous 
ducts, a triangular configuration of grouped microcalcifications 
has diagnostic significance in respect of DCIS (15). 
Even though several attempts have been made to 
differentiate radiologically between benign and malignant 
calcifications (16-18), most investigators found no conclusive 
difference between mammograms of patients with benign or 
malignant biopsies when films were analyzed for size, shape, 
and radiographic density of individual or clustered 
calcifications (12,19-21). The only exception is that none 
of the malignant clusters contained less than five calcifi-
cations (12,21,22), although in extremely rare cases even 
carcinomas with less than five microcalcifications have been 
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Table 4: Review of literature of microcalcifications without palpable mass 
No. of 
No. of No. of noninvasive No. of 
nonpalpable No. of % of invasive carcinoma positive 
microcalc. carcinoma carcinoma carcinoma DCIS/LCIS lymph nodes 
Rogers & Powell, 1972 (22) 
Murphy & DeSchryver-
Kecskemeti, 1978 (19) 
Roses et al, 1980 (29) 
LSnyi & Citoler, 1981 (18) 
Colbassani et al, 1982 (20) 
Hoehn et al, 1982 (36) 
Powell et al, 1983 (21) 
Chetty et al, 1983 (24) 
Meyer et al, 1984 (25) 
Present series 
46 19 41.3 11 
15 
52 
135 
55 
26 
282 
103 
203 
173 
7 
17 
36 
15 
4 
47 
25 
45 
51 
46.7 
32.7 
26.7 
27.3 
15.4 
16.7 
24.3 
22.2 
29.5 
3 
10 
0 
8 
0 
11 
10 
21 
4 0 
6 1 
33 3 
7 0 
4 0 
26 10 
15 
22 7 
reported (23). Thus microcalcifications on the mammogram are 
not pathognomonic of carcinoma, but represent a high-risk area 
of the breast that requires a biopsy for histologic examination. 
For the entire procedure, including preoperative locali-
zation, close cooperation is required between the surgeon, 
radiologist, and pathologist. A postoperative mammogram should 
be performed if there is doubt concerning the actual removal 
of the grouped microcalcifications in question. 
A search of the literature revealed that only a few 
large series of nonpalpable calcifications have been published 
so far (Table 4). The malignancy rate in those reports varies 
between 15% and 46% in mostly small series and from 16% to 
26% in the larger series (18,21,24,25). Our malignancy rate 
of 29.5% compares favorably with these figures. 
Breast cancers detected by mammography alone and that 
are nonpalpable are more often noninvasive, smaller in size, 
and more often associated with negative axillary nodes than 
those that presented with a palpable mass (24,26,27). The same 
seems to apply to nonpalpable malignant calcifications. 
Powell et al (21) showed in their large series that 36 (77%) 
of the total number of 47 cancers were noninvasive: 26 were 
DCIS and 10 were LCIS. In our series of 51 cancers, 29, or 
more than half (56.8%), were also noninvasive: 22 DCIS and 
seven LCIS. 
Many of those breast tumors that are invasive have no 
nodal extension. Positive axillary nodes vary in the 
literature between 2% and 25% (20-22,26,28,29). We found 
axillary involvement or distant metastases in 11% of the 
fully évaluable axillae, which warrants the expectation that 
this group of occult breast cancers might have a better 
prognosis. 
It should be noted that no nonpalpable microcalcifications 
proved to be malignant on histopathologic examination in 
patients younger than 4 0 years of age. Moreover, in the 
Breast Cancer Detection Demonstration Project, sponsored by 
the American Cancer Society, the rate of breast cancer in the 
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35- to 39-year-old age-group was extremely low (30). However, 
in Egan's (12) series 12% of all biopsy-proved malignant 
calcifications were detected in the 30- to 39-year-old age-
group. Apparently, the age of the woman is not helpful in 
differentiating benign from malignant lesions. 
After biopsy of the suspicious occult calcifications and 
subsequent histologic examination of the radiographed and 
fixed specimens, no malignancy could be found in 70.5% of 
our biopsies. In half of the cases (51.6%), the micro-
calcifications were associated with simple fibrocystic 
disease. However, in one quarter of the benign biopsies 
(25.4%), mastopathy with cell atypia was found, while 
papillomatosis was the final diagnosis in 18 biopsies (14.8%). 
This means that 40.2% of the benign biopsies showed some degree 
of proliferative unrest. The risk of subsequent development 
of breast cancer among women whose benign biopsies showed some 
degree of hyperplastic lesions or atypical changes ranges from 
two to five times that of the general population (31-33). 
Since 'epithelial proliferative disease of the breast' (33) 
is predictive of increased subsequent risk, we see these 
patients every six months for a physical and annually for 
radiographic follow-up. 
Calcifications are more commonly found in DCIS and less 
frequently within the LCIS (34), since in LCIS the calcifi-
cations, if present, are localized in adjacent benign fibro-
cystic tissue (35). 
Clustered punctate calcifications without an associated 
mass on the mammogram in the absence of any clinical findings 
is the earliest possible sign of breast cancer. To a physician 
it is almost axiomatic that detection at this 'early' stage 
would result in a better prognosis for the patient. However, 
caution is required in drawing this conclusion because of the 
effect of lead time and length time bias inherent in screening. 
The low rate of positive axillary nodes is promising and may 
indicate an early stage of disease, but the results of additional 
long-term survival studies have to be awaited. 
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II. 5 SUMMARY 
Microcalcifications constitute an important part of 
nonpalpable breast lesions and may be the first sign of a breast 
carcinoma. Between 1975 and 1984, 150 consecutive patients with 
clusters of at least five microcalcifications without palpable 
findings as the only indication for biopsy were treated. One 
hundred seventy-three groups of microcalcifications were 
excised and 51 malignancies were detected (29.5%). Most of 
the malignant lesions were noninfiltrating (56%). Axillary or 
distant metastases occurred in 11% of the fully évaluable 
cases. This warrants the expectation that these patients have 
a very favorable prognosis. Breast biopsy for nonpalpable-
clustered microcalcifications is a feasible and valuable 
procedure. Close cooperation is required between the surgeon, 
radiologist, and pathologist. 
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111.1 INTRODUCTION 
The surgeon who is going to perform a breast biopsy is 
faced with a decision-making problem. Although other risk 
factors have also to be taken into account he will heavily 
depend upon the report of the pathologist. In the past frozen 
section examination has proved to be a highly reliable method 
in breast biopsies because of palpable lesions (1,2). Thus 
in case of malignancy the biopsy could be followed b^ 
mastectomy or breast conserving surgery in the same session 
(one-stage procedure) instead of awaiting the routine paraffin 
section report and performing further surgery at a later date 
(two-stage procedure). 
We have undertaken to review our 10-years experience with 
nonpalpable breast lesions and the place of the frozen section 
diagnosis. 
111.2 MATERIALS AND METHODS 
The data of 359 biopsies performed because of clinically 
occult mammographie lesions form the basis of this study. All 
patients were treated at the St. Radboud University Hospital, 
Nijmegen, The Netherlands, in the period between 1.1.1975 
and 1.1.1985. Almost half of them were detected as a result of 
an ongoing population screening programme and the greater half 
were referred to the surgical out-patients' department as a 
result of individual screening. 
The 359 mammographie abnormalities occurred in 321 
patients: 287 patients had one biopsy, there were 30 patients 
with two biopsies and 4 patients with three biopsies. These 
321 patients underwent 346 operations since in 13 cases 
two mammographie lesions were excised during the same operation. 
All patients were female. All case-sheets were checked for the 
following items: age of the patient, year of the diagnosis, 
character and site of the mammographie lesion(s), reason of 
mammography, whether or not frozen section was performed, in 
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which cases the initial frozen section diagnosis was deferred 
to the permanent sections and the final paraffin section 
report. 
In all but one confirmation was obtained, almost 
exclusively by specimen radiography and in a few cases by post-
surgical repeat mammography that the correct mammographie 
abnormality had been excised. In principle frozen section was 
performed guided by the radiogram of the in toto or sliced 
specimen (3). When any doubt existed a provisionary report was 
given but the definitive diagnosis was deferred to the paraffin 
sections. In recent years frozen section was not performed 
anymore in all cases with microcalcifications only or with 
very small solid tumours of less than 5 mm (4). The data 
presented here do not refer to the number of patients, but to 
the number of specimens examined. 
III.3 RESULTS 
The 359 biopsies in 321 patients for nonpalpable breast 
lesions constituted 24.3% of the total of 1475 breast biopsies 
performed on in-patients during this 10-year period. 
Clinically occult cancer was proved in 118 biopsies 
representing a malignancy rate of 32.9%. Since 1982 the 
predictive value positive of the mammographie breast cancer 
test (= number of screen-detected cancers/number of biopsies) 
has increased considerably up to 68% in 1984 (Figure 1). 
Table 1 shows the reasons for mammography. The malignancy 
rate of the biopsies amongst the population-screened women is 
35.6% and similar to the 30.3% of the biopsies in women 
discovered by individual screening. 
The age distribution is shown in Figure 2. The patients 
with benign biopsies had an average age of 49.8 years (range 
19 to 75), while patients with malignant biopsies had an 
average age of 57.2 years (range 37 to 76). Below the age of 
40 years no malignancy was encountered except for one patient 
with lobular carcinoma in situ (LCIS). As can be seen from the 
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Figure 1: Predictive value of the mammographie breast cancer 
test (predictive value positive) = number of screen 
detected breast cancer cases/number of biopsies 
p r e d i c t i v e v a l u e 
Figure 2: Age distribution of benign and malignant biopsies 
because of nonpalpable mammographie lesions 
total number of biopsies 
kWI invasive carcinoma 
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Table 1: Reasons for mammography in 359 biopsies because of 
clinically occult breast lesions 
Population screening 
total 
number 
174 
number percentage 
malignant malignant 
62 35.6 
Individual screening 185 
breast complaints 99 
control 'premalignant 
lesions' 33 
contralateral mastectomy 27 
carcinophobia 9 
positive family history 3 
other reasons 14 
56 30.3 
28 
16 
8 
0 
2 
2 
28.3 
48.5 
29.6 
0 
66.7 
14.3 
same histogram the malignancy rate increases with the higher 
age groups. Below 55 years of age there were 50 malignancies 
in 221 biopsies representing 22.6%, while in patients of 
55 years and over 68 malignancies or 49.3% were found out of 
138 biopsies. The average age of the patients with invasive 
breast cancer is 59.8 years (range 42 to 76) and in patients 
with non-invasive breast cancer (ductal carcinoma in situ = 
DCIS, and LCIS) the average age is 52.1 years (range 37 to 68) 
The location of the nonpalpable breast lesions is 
presented in Table 2. The upper outer quadrant was by far the 
commonest site containing 46.2% of the biopsies and 50.8% of 
the malignancies. The lower inner quadrant was the least 
frequent location. The left/right ratio was 1.22 for the 
biopsied mammographie abnormalities and 1.19 for the occult 
cancers. 
Table 3 shows that the majority of the mammographie 
lesions consists of clustered microcalcifications only: 188 
or 52.4% of all lesions. The malignancy rate of different 
mammographie lesions varies greatly. When a stellate-shaped 
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Table 2: Location of 3 59 nonpalpable breast lesions 
Quadrant Number of biopsies Number of malignancies 
Right Left Total % Right Left Total % 
Central 
Upper outer 
Upper inner 
Lower outer 
Lower inner 
Total 
28 
80 
28 
12 
14 
162 
35 
86 
41 
21 
14 
197 
63 
166 
69 
33 
28 
359 
17.6 
46.2 
19.2 
9.2 
7.8 
100.0 
7 
31 
8 
4 
4 
54 
12 
29 
12 
4 
7 
64 
19 
60 
20 
8 
11 
118 
16.1 
50.8 
17.0 
6.8 
9.3 
100.0 
mass is detected, two out of every three biopsies proves to 
be malignant. In case of microcalcifications with or without 
a non-spiculated density the malignancy rate is 28.6% and 
32.4%. A circumscribed or nodular density yields a malignancy 
in 12.7% only. 
The histology of the benign biopsies is given in Table 4. 
Of 241 benign biopsies 120 or 49.8% show simple fibrocystic 
disease. In 86 cases or 35.7% there was some form of pro-
liferative unrest: 56 biopsies or 23.2% showed fibrocystic 
disease with atypia and 30 times or 12.5% the diagnosis was 
papillomatosis. Fibroadenoma occurred in 27 or 11.2% of the 
biopsies. Noteworthy is the fact that benign scar tissue may 
manifest itself as a stellate-shaped mass. 
In Table 5 the histology of the malignant biopsies is 
presented in correlation with the mammographie findings. Of 
the whole group of 118 malignant biopsies 59 (50.0%) were 
infiltrating carcinomas, either ductal or lobular, including 
one patient with Paget's disease with infiltrating ductal 
cancer. Well-differentiated tubular carcinoma was a frequent 
finding (17 cases or 14.4%) of which 14 cases were detected 
as a stellate-shaped mass. There were 40 non-invasive breast 
cancers (33.9%): 32 DCIS and 8 LCIS. Of these 40 non-invasive 
carcinomas 33 occurred in the group with microcalcifications 
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Table 3: Mammographic-histopathologic correlation in 359 non­
palpable breast lesions 
Martirography Total number Number malignant % malignant 
Circumscribed or nodular mass 71 9 12.7 
Clustered microcalcifications 188 61 32.4 
Mass with microcalcifications 49 14 28.6 
Stellate-shaped mass 51 34 66.7 
Total 359 118 32.9 
only: 26 DCIS and 7 LCIS. Of note is also the fact that no 
in situ cancers were found in the group with the stellate-
shaped mass. Others (1.7%) included one case of basal cell 
caroinoma of the skin and one patient with a non-Hodgkin's 
lymphoma. 
Table 6 gives the correlation between the peroperative 
frozen sections and the final paraffin sections. No frozen 
sections were performed in 62 cases (17.3%), mostly when 
microcalcifications alone were present (47 biopsies) or when 
the circumscribed density was too tiny (10 biopsies). In only 
a few cases no frozen section was done on patient's request. 
On the basis of the 62 paraffin sections 7 invasive and 
17 non-invasive cancers were diagnosed, most of them belonging 
to the group with microcalcifications only: 4 χ invasive 
carcinoma and all 17 non-invasive carcinomas (14 χ DCIS and 
3 χ LCIS). 
In 44 occasions (12.2%) frozen section was performed but 
the definitive diagnosis deferred until the paraffin sections 
were ready. In 22 cases (50% of the deferrals) there was some 
degree of proliferative unrest: 18 times a proliferative 
lesion with atypia and 4 times papillomatosis. In 11 cases 
(25% of the deferrals) malignancy was the final diagnosis: 
3 χ invasive cancer, 4 χ DCIS, 3 χ LCIS and 1 χ malignant 
lymphoma. 
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Table 4: Histology of benign biopsies 
Histology Mammography 
Circumscribed or Clustered Mass with 
nodular mass microcalc. microcalc. 
No. % No. % No. % 
Simple fibrocystic disease 30 48.4 65 51.2 16 45.7 
Fibrocystic disease with 
atypia 
Papillomatosis 
Fibroadenoma 
Inflammation 
Post-biopsy scar tissue 
Others 
Total 
13 
7 
10 
1 
1 
62 
21.0 
11.3 
16.1 
1.6 
1.6 
100.0 
33 
18 
9 
-
2 
127 
26.0 
14.1 
7.1 
-
1.6 
100.0 
5 
4 
8 
1 
1 
35 
14.3 
11.4 
22.8 
2.9 
2.9 
100.0 
Stellate-
shaped mass 
No. % 
9 52.9 
5 29.4 
1 5.9 
2 11.8 
17 100.0 
Total 
No. % 
120 49.8 
56 23.2 
30 12.5 
27 11.2 
2 0.8 
2 0.8 
4 1.7 
241 100.0 
Table 5: Histology of malignant biopsies 
Histology Mammography 
Infiltrating carcinoma 
(ductal or lobular) 
Tubular carcinoma 
M. Paget with infiltrating 
ductal carcinoma 
DCIS 
LCIS 
Others 
Total 
Circumscribed or 
nodular mass 
No. % 
55.6 
11.1 
22.2 
11.1 
100.0 
Clustered 
microcalc. 
No. % 
24 
2 
39.4 
3.3 
1 1.6 
26 42.6 
7 11.5 
1 1.6 
61 100.0 
Mass with 
microcalc. 
No. % 
64.3 
4 28.6 
1 7.1 
14 100.0 
Stellate-
shaped mass 
No. % 
20 58.8 
14 41.2 
34 100.0 
Tota 
No. 
58 
17 
1 
32 
8 
2 
118 
1 
% 
49.2 
14.4 
0.8 
27.1 
6.8 
1.7 
100.0 
DCIS = ductal carcinoma in situ 
LCIS = lobular carcinoma in situ 
ISI 
Table 6: Concordance between frozen and paraffin sections in biopsies performed because of nonpalpable 
mammographie lesions 
Histology 
Correct diagnosis: 
benign 
malignant 
False positive 
False negative 
Deferred 
No frozen section 
Circumscribed or 
nodular mass 
No. 
44 
5 
0 
0 
12 
10 
% 
62.0 
7.0 
0 
0 
16.9 
14.1 
Mammography 
Clustered 
microcalc. 
No. 
84 
29 
0 
4 
24 
47 
% 
44.7 
15.4 
0 
2.1 
12.8 
25.0 
Mass with 
microcalc. 
No. 
28 
10 
0 
2 
5 
4 
% 
57.1 
20.4 
0 
4.1 
10.2 
8.2 
Total 
Sensitivity 
Specificity 
Accuracy 
71 100.0 
100.0 
100.0 
100.0 
188 100.0 49 100.0 
87.9 
00.0 
96.6 
83.3 
100.0 
95.0 
Stellate-
shaped mass 
No. 
12 
32 
2 
1 
3 
1 
% 
23.5 
62.7 
3.9 
2.0 
5.9 
2.0 
51 100.0 
97.0 
85.7 
93.6 
Total 
No. 
168 
76 
2 
7 
44 
62 
359 
% 
46.8 
21.2 
0.6 
1.9 
12.2 
17.3 
100.0 
91.6 
98.8 
96.4 
in 
A correct diagnosis, whether benign or malignant, was 
achieved with frozen section technique in 244 biopsies or 
68.0%. 
False negative reports constituted 1.9% (7 cases) of the 
total number of biopsies: 2 χ invasive carcinoma of which 
one tubular carcinoma, 2 χ DCIS, 2 χ LCIS and 1 χ basal cell 
carcinoma. 
In 2 cases a false positive report had been given. Both 
were radiographically characterized by a spiculated mass. One 
patient was reported to have a LCIS and underwent no further 
surgery. Paraffin section diagnosis revealed a 4 mm focus of 
sclerosing adenosis and no further abnormalities. 
The second report had more serious consequences. Frozen 
section diagnosis was an extensive intraductal cancer without 
clear signs of invasive growth (DCIS). After an infra­
clavicular apical biopsy had revealed no signs of secondaries 
a radical mastectomy was performed m the same session because 
of violation of the underlying pectoralis fascia during 
excision of the deep lying radiographical density. On permanent 
paraffin sections five locations of a so-called 'radial scar 
lesion' were found in several quadrants and foci of intra­
ductal epithelial proliferations with severe atypia. There was 
no invasive growth and all lymph nodes were free of disease. 
III.4 DISCUSSION 
In recent years evidence is emerging that mammographie 
screening may reduce the risk of dying from breast cancer (5-9). 
As a result of this there is a justifiable growing demand for 
more radiographical services for early detection of breast 
cancer both from the public and the medical profession. 
Consequently, clinicians will increasingly be confronted with 
nonpalpable mammographie lesions. Leaving apart the surgical 
problem of correctly removing the tiny abnormalities the 
attending doctor will like to know the 'yield' of these 
biopsies. 
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In our series the malignancy rate is 32.9% and compares 
favourably with the frequencies in other large series: 18.2-
28.9% (10-14). The malignancy rate rises with increasing age 
and also depends upon the type of mammographie abnormality. 
The lowest figures of malignancy were found in the group 
with a nodular or circumscribed mass and the highest in the 
group with the stellate-shaped masses. Calcifications yielded 
intermediate results which is in accordance with the tendency 
in other smaller series (11,14). 
A peculiar finding was the sudden increase of the 
predictive value positive since 1982. Since all mammograms 
had been reported by the same radiologist this may partly be 
due to increasing experience. Another influencing factor may 
be the advent in January 1982 of technical improvements like 
a mammographie grid and a microfocus of 0.09 mm allowing a 
magnification of 1.5 to 2 times and visualizing more details. 
Echography has only seldom been used by us in nonpalpable 
breast lesions because its resolution of ^ to 1 cm is often 
unable to differentiate between small solid masses and cysts, 
especially in fatty breast tissue. 
Suspicious mammograms detected by population or individual 
screening have a similar predictive value positive. This means 
that suspicious mammograms should be considered on its own 
merits and should not be influenced by the fact that they 
belong to women in certain high-risk groups. Fear seems to be 
a bad adviser as no woman with carcmophobia m this small 
series had cancer. 
The left/right ratio of the occult cancers is 1.19 which 
is in agreement with the left predominance of breast carcinoma 
reported by others (15). An explanation of the phenomenon is 
that the occurrence of breast cancer is tissue volume 
dependent. Measuring the relative breast volume from the 
mammogram in asymptomatic women the left breast was larger in 
55% (15). The same explanation applies to the predominance of 
carcinoma in the upper outer quadrant, which is largest. 
The non-invasive cancer patients in our study are on 
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average 7.7 years younger than the patients with invasive 
cancer. This age discrepancy supports the view that in situ 
cancer is a pre-invasive lesion in a transitory stage of 
malignant transformation into invasive cancer. Other support 
for this view is found in retrospective studies of pre-invasive 
ductal carcinoma treated by biopsy only and revealing a 
subsequent development into invasive carcinoma in 28-67% (16-17). 
Of interest is the fact that 35.7% of the benign biopsies 
showed some degree of proliferative unrest. The risk of sub-
sequent development of breast carcinoma amongst patients with 
atypical proliferative lesions is two to five times higher than 
that of the general population (18-20) . That is why we are 
following these women with physical examination every six 
months and an annual mammogram. 
Cheek and Sears found surprisingly only three DCIS in 
57 carcinomas as a result of 314 biopsies because of non-
palpable mammographie lesions (10). Others reported a much 
higher frequency of 40.3-72.7% pre-invasive or in situ lesions 
amongst occult breast cancers (11-13). Considering our 118 
malignant biopsies, 40 or 33.9% of these were non-invasive 
and 38 of them had calcifications with or without an 
associated mass. So clustered microcalcifications represent 
an earlier stage of disease than the other types of mammo-
graphie abnormalities like circumscribed densities and 
spiculated masses do (21). 
Through the greater use of x-ray mammography the 
relatively infrequent occurrence of the slow growing tubular 
carcinoma with a favourable prognosis has risen from 2% to 9% 
in a screening setting including both palpable and non-
palpable tumours (22,23). In the latter series there were 
9 tubular carcinomas in 62 occult cancers representing 14.5%. 
Also in our experience of the 118 non-palpable cancers 17 or 
14.4% were tubular carcinomas and 14 of them became visible 
as a stellate mass on x-ray which can be explained by its 
nature of a strong desmoplastic stroma and infiltrating margins. 
The high rates of non-invasive and low grade tubular carcinomas 
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both contribute to the length bias inherent in screening. In 
contrast, fast growing tumours are relatively more often 
diagnosed clinically between two screening examinations as 
so-called interval cancers and different growth rates have 
been calculated for screen-detected interval cancers (24). 
The reliability of frozen section diagnosis of breast 
biopsies because of palpable findings is well established 
(2,25). In biopsies for non-palpable breast lesions, however, 
frozen section interpretation is considered to be difficult 
and is therefore not advocated by some authors (11,14). Only 
Cheek and Sears reported in their series of 314 biopsies that 
47 of the 57 occult cancers were diagnosed at the time of 
surgery by frozen section examination after specimen radio-
graphy had confirmed the lesion (10). Indeed specimen x-ray 
and comparison with the original mammogram are essential 
prerequisites in order to ascertain proper removal of the 
suspicious lesion. Moreover, its position in the sliced 
tissue can be determined radiographically when grossly no 
obvious suspicious lesion appears (3). In our hands the rate 
of false negative reports is 1.9%. Rosen who reviewed 556 
consecutive breast biopsies had 1.4% false negatives (25). 
However, the two series are not fully comparable since m 
our series for clinically occult lesions alone diagnosis was 
delayed or no frozen section performed in 29.5% of the cases 
while Rosen had only 5.4% of his (mostly palpable) biopsies 
deferred to permanent sections. 
False negative frozen section examination will do no harm 
provided a definite diagnosis will be given on the basis of the 
paraffin sections. Patients have to be cautioned by their 
attending surgeon that a frozen section diagnosis of benignancy 
is always provisional and that the final paraffin sections have 
to be awaited. 
Great care must be taken against false positive reports 
and in case of the faintest doubt expressed by the pathologist 
the option of deferment should prevail. In this respect the 
so-called radial scar lesion, which is a form of florid 
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sclerosing ductal adenosis, may pose diagnostic problems. 
As breast conserving surgery is gaining more and more 
acceptance the criteria for selection of patients for this 
treatment method are becoming more important. Accordingly, 
it is nowadays not sufficient anymore to know whether the 
biopsy shows malignancy or not, but more data are required 
like histological size and type, the extent of the intra-
ductal component of the tumour, the differentiation of the 
tumour and adequacy of surgical excision (26). That is why 
in recent years a shift has begun towards a two-stage procedure, 
i.e. a diagnostic breast biopsy specimen is first studied with 
permanent sections before definitive therapeutic alternatives 
are discussed with the patient (27). 
III.5 SUMMARY 
Of 359 biopsies in 321 patients because of nonpalpable 
mammographie lesions 118 or 32.9% proved to be malignant. 
Approximately half of the lesions were located in the upper 
outer quadrant. The left/right ratio was 1.22 for biopsies 
and 1.19 for occult cancers. The malignancy rate was 12.7% 
in case of a circumscribed or nodular mass, 32.4% for 
clustered microcalcifications only, 28.6% when a mass with 
microcalcifications was found and 66.7% when a stellate-
shaped mass was present. Seventy-six were invasive breast 
cancers of which 17 tubular carcinomas. There were 40 non-
invasive breast cancers: 32 DCIS and 8 LCIS, the great majority 
of them belonging to the group with clustered microcalcifi-
cations only. Others included one case of non-Hodgkin's 
lymphoma and one case of basal cell carcinoma of the skin. 
The average age of patients with invasive breast cancer was 
59.8 years (range 42-76) and in patients with non-invasive 
breast cancer 52.1 years (range 37-68). 
Frozen section examination was correlated with the final 
paraffin section report and a correct diagnosis was achieved 
in 68.0%. No frozen section examination was performed in 17.3%, 
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and in 12.2% the diagnosis was deferred to the paraffin sections. 
False negative reports were encountered in 7 cases (1.9%) and 
false positives in 2 (0.6%), both of them cases of florid 
sclerosing adenosis. Provided the pathologist is not reluctant 
to defer a diagnosis to the permanent paraffin sections the 
frozen section method is a feasible and reliable procedure, 
even in nonpalpable breast lesions. Specimen radiography of the 
in toto or sliced biopsy is, however, mandatory. It is probably 
prudent not to use this method for pure microcalcifications and 
very tiny solid masses of 5 mm and less. 
It is discussed that modern breast conserving surgery 
requires more histopathological details (type of tumour, other 
foci around the reference tumour and whether or not the 
surgical margins of the excisional biopsy or segmentectomy are 
free). Frozen section examination often cannot meet these new 
requirements and one has to rely upon the definitive paraffin 
sections in a two-stage procedure. 
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IV.1 INTRODUCTION 
The determination of oestrogen (ER) and progesterone 
receptor (PgR) activity m primary and metastatic breast cancer 
is nowadays standard medical practice since steroid-hormone 
receptors represent valuable prognostic indicators along with 
nodal status and tumour size (1-3). Hypothetically, it is 
assumed that all breast cancers are hormone-dependent from the 
beginning. In the course of their tumour life they 
dedifferentiate loosing endocrine responsiveness and becoming 
increasingly receptor-negative. To our knowledge no studies 
have ever reported the receptor activities in subclinical or 
nonpalpable breast cancer. From a tumour biological point of 
view it would be interesting to know whether the above stated 
hypothesis is valid in light of the fact that nonpalpable breast 
tumours differ from the palpable ones by their lead time which 
has been calculated at three years (4,5). 
IV.2 PATIENTS AND METHODS 
All patients were diagnosed and treated at the St. Radboud 
University Hospital, Nijmegen, in the period between 1974 and 
July,1986. 
Four groups of patients were studied for steroid receptor 
content in their tumour tissues. Firstly, patients with non-
palpable primary breast cancer, i.e. clinically occult and 
detected by mammographical means only (n=62). Secondly, patients 
with palpable operable primary breast cancer, including those 
patients with tumour stages T, ., N«- Mn according to the TNM-
classification (n=259). Thirdly, patients with locoregionally 
advanced primary breast cancer, i.e. any T. or N, with M. (n=73). 
The fourth group consisted of patients with metastatic breast 
cancer, whose receptor status was assessed at the time of their 
first relapse (n=58). The median disease-free interval of the 
latter group was 33 months. None of these patients had systemic 
adjuvant therapy in the past. 
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The breast cancer tissue specimens have all been processed 
at one laboratory for steroid receptor assays. ER and PgR 
concentrations were measured by the dextran-coated charcoal 
method with multiple-point Scatchard plot analysis as previously 
described from here (6). Only those assays with cytosol protein 
contents of >2 mg/ml were included. We considered the tissue 
specimen to be receptor-negative at a cut-off level of 10 fmol/mg 
protein, for both ER and PgR. 
Statistical analysis was performed using Fisher's Chi 
Square test (P denoted by p) and Wilcoxon's two-sample test 
iL 
(Ρ denoted by ρ ). The four groups of patients did not differ 
in mean age (p >0.1) or menopausal status (p>0.1). 
IV.3 RESULTS 
Of 62 nonpalpable breast cancers ER-positivity was seen in 37 
of 46 invasive ductal cancers (80.4%), in eight of 10 invasive 
lobular carcinomas (80%), and in three of six patients with 
ductal carcinoma in situ (50%). The PgR status was known in 57 
of those 62 cancers and was positive in 33 of 43 patients with 
invasive ductal carcinoma (76.7%), eight of nine invasive 
lobular carcinomas (88.9%), and in none of the five in situ 
ductal carcinomas (0%). 
With regard to the invasive cancers, ER activity was 
positive in 31 of 39 tumours with a diameter over 10 mm (79.5%) , 
and in 14 of 17 tumours smaller than or equal to 10 mm (82.5%) . 
PgR-positlve tumours occurred in 30 of 36 available assays of 
invasive carcinomas >10 mm (83.3%), and in 11 of 16 invasive 
carcinomas <10 mm (68.8%). 
The quantitative ER and PgR values of the 56 nonpalpable 
invasive breast cancers are given in Figure 1. The median ER 
level of 7 5 fmol/mg protein in postmenopausal women was 
significantly higher (p <0.02) than the median ER level of 
21 fmol/mg protein in premenopausal women. Conversely, the 
median PgR level of 62 fmol/mg protein in postmenopausal 
patients is lower than the median PgR value of 105 fmol/mg 
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Figure 1 : 
Absolute ER and PgR 
values in nonpalpable 
invasive breast cancer, 
related to menopausal 
status. 
protein in premenopausal patients, but reached no statistical 
significance (p >0.1). 
Table 1 demonstrates the ER and PgR status of the 
tumours in groups of patients with a different stage of the 
disease. Both receptors were analysed in 52 of the 56 invasive 
nonpalpable breast cancers. In this group of patients with 
nonpalpable primary breast cancer 84.6% had an ER-positive 
tumour whereas in the group of metastatic breast cancer 68.9% 
of the tumours were classified as ER-positive (p<0.05). For 
PgR, an even more striking loss of receptor activity was 
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TABLE 1: Steroid receptor assays in patients with primary 
(nonpalpable, palpable operable and locoregionally 
advanced) and (first) metastatic breast cancer 
Group ER PgR 
Positive Negative Positive Negative 
n % n % n % n % 
Nonpalpable primary 
breast cancer (n=52) 44 84.6 8 15.4 41 78.8 11 21.2 
Palpable operable 
primary breast cancer 180 69.5 79 30.5 167 64.5 92 35.5 
(n=259) 
Locoregionally advanced 
primary breast cancer 49 67.1 24 32.9 43 58.9 30 41.1 
(n=73) 
F i r s t metastastic 
breast cancer (n=58) 40 68.9 18 31.1 27 46.6 31 53.4 
obse rved : 78.8% P g R - p o s i t i v e tumours in t he nonpa lpab le group 
v i a 64.5% in t h e p a l p a b l e o p e r a b l e group and 58.9% in t h e 
l o c o r e g i o n a l l y advanced group t o only 46.6% in t h e m e t a s t a t i c 
group (p<0 .005) . 
The observed s h i f t in r e c e p t o r phenotype was a l s o seen when 
both r e c e p t o r s were c o n s i d e r e d s i m u l t a n e o u s l y , a s shown in 
Table 2: ER+ PgR+ tumours were observed in 71.1% of t h e p a t i e n t s 
in t he nonpa lpab le b r e a s t cancer g roup , g r a d u a l l y d e c r e a s i n g 
t o only 41.3% i n t h e m e t a s t a s t i c group (p<0 .005) . E r - PgR-
tumours i n c r e a s e d from 7.7% in t he nonpa lpab l e group t o 25.8% 
i n t h e m e t a s t a t i c group (p<0 .02) . The remain ing phenotypes 
ER+ PgR- and ER- PgR+ did not show any s i g n i f i c a n t d i f f e r e n c e 
between t h e four groups s t u d i e d ( p > 0 . 1 ) . 
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TABLE 2 : R e c e p t o r p h e n o t y p e s i n p a t i e n t s w i t h p r i m a r y (non-
p a l p a b l e , p a l p a b l e o p e r a b l e and l o c o r e g i o n a l l y 
a d v a n c e d ) and ( f i r s t ) m e t a s t a t i c b r e a s t c a n c e r 
Group Receptor phenotype 
ER+ PgR+ ER+ PgR- ER- PgR+ ER- PgR-
n % n % n % n % 
Nonpalpable primary 
b r e a s t cancer (n=52) 37 71.1 7 13.5 4 7.7 4 7.7 
Palpable operable primary 
b r e a s t cancer (n=259) 149 57.5 31 12.0 18 6.9 61 23.5 
Docoregionally advanced 
primary b r e a s t cancer 35 47.9 14 20.0 8 10.9 16 21.9 
(n=73) 
F i r s t m e t a s t a t i c 
b r e a s t cancer (n=58) 24 41.3 16 27.6 3 5.2 15 25.8 
I V . 4 DISCUSSION 
By t h e t i m e a b r e a s t c a n c e r h a s r e a c h e d a m a m m o g r a p h i c a l l y 
d i s c e r n a b l e s i z e of 5 mm, a l r e a d y 22 d o u b l i n g s o r b e t w e e n h a l f 
and t w o - t h i r d of i t s t u m o u r l i f e - s p a n h a v e p a s s e d . A n o t h e r 14 
d o u b l i n g s f u r t h e r i s u n i f o r m l y l e t h a l ( 7 , 8 ) . T h i s means t h a t 
n o n p a l p a b l e b r e a s t c a n c e r i s s t i l l d e t e c t e d r e l a t i v e l y l a t e 
i n t h e c o u r s e of i t s tumour l i f e . 
The a b o v e p r o v e n s h i f t of r e c e p t o r p h e n o t y p e from a h i g h 
f r e q u e n c y o f ER+ PgR+ t u m o u r s i n n o n p a l p a b l e b r e a s t c a n c e r 
t o w a r d s l e s s f r e q u e n t ER+ PgR+ and more ER- PgR- t u m o u r s i n 
p a l p a b l e and a d v a n c e d b r e a s t c a n c e r , s u g g e s t s t h a t t h e e a r l i e r 
s t a g e s , a f t e r l e s s d o u b l i n g t i m e s and n o t y e t d e t e c t a b l e by 
mammograph ie m e a n s , may c o n t a i n s t e r o i d r e c e p t o r s i n e v e n 
h i g h e r f r e q u e n c y , r e a c h i n g 100% a t i t s i n c e p t i o n . 
I t s h o u l d be n o t e d t h a t t h e l o s s o f PgR i n t h e c o u r s e of 
t i m e i s m o r e m a r k e d t h a n t h e l o s s o f ER, w h i c h i s i n k e e p i n g 
w i t h p r e v i o u s d a t a on s e q u e n t i a l b i o p s i e s i n a d v a n c e d b r e a s t 
c a n c e r , c l e a r l y s h o w i n g t h a t t h e i n c o n s i s t e n c y i n PgR i s 
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significantly higher than in ER (3,9). 
Two sources of bias, however, should be recognized. It is 
well known that nonpalpable breast cancers found by mammographie 
screening predominantly are relatively slow-growing tumours. 
Tumours with a low proliferation activity tend to be ER-
positive (10). So the way of detection of nonpalpable breast 
cancer could have influenced the present analysis. However, 
for patients with advanced disease, the location of accessible 
skin and lymph node metastases could have increased the actual 
number of ER-positive tumours, because non-accessible visceral 
metastases are more often ER-negative (11). 
For an adequate Scatchard plot analysis on a micro scale 
at least 100 mg of tumour is required, which means approximately 
a cube of tissue 0.5 cm on each side. Of our 17 invasive 
carcinomas £10 mm all had diameters between six to 10 mm, 
except for one which was smaller than five mm, but had a large 
in situ ductal component. 
Although the long-term prognosis of nonpalpable breast 
cancer is extremely good (12-14), some will develop to advanced 
disease. It may be concluded from the above results that the 
hormone-responsiveness of metastases after nonpalpable breast 
cancer is not automatically predicted by its primary tumour 
receptor status. 
The development of assays based on monoclonal antibodies 
against ER (not yet for PgR) has opened new perspectives for 
measuring steroid-hormone receptors in small tissue specimens 
(15). It is expected that in the near future more data will 
become available on the smallest and earliest possible stages 
of breast cancer. 
IV.5 SUMMARY 
Four groups of patients,comparable in mean age and 
menopausal status, with i) nonpalpable primary breast cancer, 
ii) palpable operable primary breast cancer, iii) loco-
regionally advanced primary breast cancer, and iv) first 
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metastatic breast cancer, were studied in respect of their 
steroid receptor phenotype. A significant shift in receptor 
phenotype (ER+ PgR+) was observed from nonpalpable primary 
breast cancer (71%) via palpable operable (58%) and loco-
regionally advanced primary breast cancer (48%) to first 
metastatic breast cancer (41%). A reversed extrapolation 
of these figures supports the hypothesis that every breast 
cancer contains steroid receptors and is hormone-dependent 
from its inception. 
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Chapter V 
MULTICENTRICITY IN NONPALPABLE BREAST CARCINOMA 
AND ITS IMPLICATIONS FOR TREATMENT 
J.G.M. Tinnemans, Th. Wobbes, R.F. van der Sluis, 
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The pathologic and radiologic data used in this chapter are 
based on the studies of Dr. R. Holland and Dr. J.H.C.L. Hendriks 
from the Departments of Pathology and Radiology of the 
St. Radboud University Hospital in Nijmegen 
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V.l INTRODUCTION 
In the past decade, breast conserving surgery in the 
management of operable breast carcinoma has gained and is 
still gaining more and more acceptance both among women and 
physicians. Many surgeons were encouraged by the preliminary 
results of Veronesi and co-workers (1) who, in a prospective, 
randomized study, reported comparable recurrence and five 
year survival rates in patients with T.Np. lesions who under-
went either radical mastectomy or quadrantectomy, axillary 
dissection, and radiation therapy to the breast. Opponents, 
however, claim that as time passes, more and more therapeutic 
failures will come forward due to further disease in the 
treated breast. Such disease may be regarded as a true local 
recurrence or as a second primary tumor in the ipsilateral 
breast. 
A basic problem in a discussion of breast conserving 
surgery is the rate of residual tumor in the remaining 
breast and the question of how this can be dealt with 
adequately by radiotherapeutic means (2). Residual tumor may 
either be due to incomplete excision of the primary malignancy 
or to other foci of carcinoma elsewhere in the breast. 
Although much is known regarding the multifocality of 
palpable breast cancer with reported incidences between 30 
and 60 percent (3-8), much less data are available on non-
palpable breast carcinomas (9). Theoretically, one might 
expect figures of the same magnitude. This study was under-
taken to test this hypothesis. 
V.2 MATERIAL AND METHODS 
Between January 1, 1975 and December 31, 1983, 300 
consecutive women were biopsied at the department of general 
surgery of the St. Radboud University Hospital because of 
nonpalpable, radiographically suspicious abnormalities judged 
to be indicative of carcinoma of the breast. Patients were in 
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part drawn from a population screening program within the 
city of Nijmegen aimed at the whole female population over 
35 years of age (10) and in part from our surgical out-
patient department where patients were seen for breast 
complaints or for follow-up of previous breast cancer. 
The following radiographic findings mandated a 
recommendation for biopsy: clustered fine microcalcifications 
of five or more per square centimeter, a nodular or well-
circumscribed mass (not suggestive of a cyst) with or 
without microcalcifications, and a stellate-shaped mass. 
All mammographie abnormalities were clinically occult. Since 
1977, biopsy of the nonpalpable masses was aided by a needle 
localization technique using a self-retaining hooked wire (11). 
In general, invasive and minimally invasive carcinomas, 
whether ductal or lobular, were treated by radical or 
modified radical mastectomy. Until 1977, however, central 
and medial invasive cancers were treated by simple total 
mastectomy combined with irradiation of regional lymph nodes. 
Ductal carcinoma in situ was treated by the same methods. 
Patients with lobular carcinoma in situ did not undergo 
mastectomy but had frequent follow-up examinations. 
Since 1978, all mastectomy specimens were studied 
systematically according to the method of Egan (12), 
correlating radiographic and microscopic findings. With this 
method, the chilled breast specimen was sliced at a thickness 
of 5 mm and subsequently each slice was radiographed. Tissue 
blocks were taken from all grossly and radiographically 
suspicious areas, in addition to some randomly chosen ones 
from each quadrant and the nipple. On average, 20 blocks of 
each mastectomy specimen were obtained ard examined (8). The 
data before 1978 were studied retrospectively from the routine 
pathology reports. 
Multicentricity or multifocality was defined as the 
presence of any ductal or lobular carcinoma, whether invasive, 
noninvasive, or both, in a quadrant other than the quadrant 
harboring the primary tumor. In the case of a retromamillary 
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Table 1: Nonpalpable Breast Carcinoma 
TYPE OF CARCINOMA CASES 
Invasive carcinoma (n=65) 
Invasive ductal carcinoma 51 
Invasive lobular carcinoma 7 
Paget's disease 1 
Minimally invasive ductal carcinoma (<5 mm) 6 
Noninvasive carcinoma (n=35) 
Ductal carcinoma in situ 27 
Lobular carcinoma in situ 8 
Others (n=2) 
Malignant lymphoma (non-Hodgkin's) 1 
Basal cell carcinoma 1 
Total 102 
or central tumor, multicentricity was considered only if 
additional cancer foci were demonstrable at a distance of at 
least 5 cm beyond the nipple and vice versa. Residual 
carcinoma was considered to be any cancerous breast tissue 
left behind after biopsy of the mammographically suspicious 
lesion. Since all lesions were impalpable an excisional 
biopsy was undertaken in all cases and confirmed by radio-
graphy . 
V.3 RESULTS 
The 335 biopsies undertaken in 300 patients because of 
nonpalpable mammary lesions represented 25.2 percent of the 
total of 1,329 breast biopsies performed on in-patients 
during the nine year period of study. A malignancy was 
encountered in 102 cases (30.4 percent of the total number 
of biopsies) or 96 patients (32 percent of the total number 
of patients). 
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When dividing the occult cancers into subgroups based 
on histologic type and degree of invasion, there were 65 
invasive cancers, including 6 minimally invasive ductal 
carcinomas (£5 mm), and 35 noninvasive carcinomas (Table 1). 
Twenty-seven of the biopsies showed ductal carcinoma m situ, 
and lobular carcinoma in situ was detected eight times. In 
one case, a localized malignant non-Hodgkin's lymphoma was 
found. 
Of the entire group of 100 primary breast cancers, 85 
were of ductal origin and 15 were of the lobular small cell 
type. Of the 65 patients with invasive carcinoma, a modified 
radical or simple total mastectomy was undertaken in 56 and 
consequently, the mastectomy status became known. One 
patient had two generous biopsies performed in different 
quadrants of the same breast, both of which revealed 
malignancy. Because of malignant secondary disease in the 
infraclavicular apical biopsy specimen, this patient did 
not undergo a mastectomy but was treated with radiotherapy. 
Therefore, the mastectomy status was known in 57 patients 
(88 percent) with invasive carcinoma. Of the 35 patients 
with noninvasive carcinomas, 23 had a modified radical or 
simple total mastectomy and three patients had a subcutaneous 
mastectomy. Thus in 26 patients (74 percent) with non-
invasive carcinoma mastectomy specimens were évaluable. 
Using the definition of multicentricity outlined herein, 
of the entire group of 83 breasts studied, 39 or 47 percent 
had multifocal disease (Table 2 ) . When primary invasive 
carcinomas are considered, the overall rate of multifocality 
was 27 of 57 breasts or 47.4 percent, whereas the multi-
focality rate of the primary noninvasive cancers was 12 of 
26 breasts or 46.2 percent. 
Invasive foci of cancer within a quadrant other than 
the one containing the primary tumor were demonstrable in 
15 mastectomy specimens, representing 15 of 57 (26.3 percent) 
of the invasive cancers or 15 of 83 (18.1 percent) of the 
whole group. The remaining multicentric foci of noninvasive 
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Table 2: Multifocality of Nonpalpable Breast Cancer 
3 
30 
14 
. . 
14 
DCIS 
DCIS 
LCIS, 
LCIS, 
, 3 
27 
ДО 
, 1 
, 1 
12 
Mastectomy Other foci 
Primary diagnosis performed Unifocal of cancer* 
Invasive ductal carcinoma 44 25 IDC, 9 
MIDC, 3 
DCIS, 3 
LCIS, 4 
Invasive lobular carcinoma 6 2 ILC, 3 
DCIS, 1 
Invasive Paget's disease 1 .. DCIS, 1 
Minimally invasive ductal 
carcinoma (£5 mm) 6 
Total invasive cancer 57 
Ductal carcinoma in situ 25 
Lobular carcinoma in situ 1 
Total noninvasive cancer 26 
* Values refer to the number of patients. 
DCIS = ductal carcinoma in situ; IDC = invasive ductal 
carcinoma; ILC = invasive lobular carcinoma; LCIS = lobular 
carcinoma in situ; MIDC = minimally invasive ductal 
carcinoma (<5 mm). 
cancer were encountered in 24 cases (28.9 percent of the 
whole group): 18 had other foci of ductal carcinoma in situ 
and multifocal lobular carcinoma in situ was seen in six. 
When tumors were divided according to histologic type, 
multicentricity was present in 34 (44.7 percent) of the 76 
primary ductal carcinomas and in five (71.4 percent) of the seven 
primary lobular carcinomas. When any cancerous tissue outside 
the biopsy cavity and not limited to another quadrant of the 
breast was included, residual carcinoma was present in 50 
of 83 cases (60.2 percent) (Table 3). In cases of primary 
invasive carcinoma, residual carcinoma was found in 33 of 
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Table 3: Residual Carcinoma after Excisional Biopsy for 
Nonpalpable Breast Cancer 
Mastectomy No residual Residual 
Primary diagnosis performed carcinoma carcinoma* 
Invasive ductal 
carcinoma 
Invasive lobular 
carcinoma 
Invasive Paget's 
disease 
Minimally invasive 
ductal carcinoma 
(<5 mm) 
Total invasive 
cancer 
44 21 
1 
6 
57 24 
IDC, 13 
MIDC, 3 
DCIS, 3 
LCIS, 4 
IDC, 1 
ILC, 3 
DCIS, 1 
DCIS, 1 
DCIS, 4 
33 
Ductal carcinoma 
in situ 
Lobular carcinoma 
in situ 
Total noninvasive 
cancer 
25 
1 
26 
DCIS , 
LCIS , 
LCIS , 
15 
1 
17 
* Values refer to the number of patients. 
DCIS = ductal carcinoma in situ; IDC = invasive ductal 
carcinoma; ILC = invasive lobular carcinoma; LCIS = lobular 
carcinoma in situ; MIDC = minimally invasive ductal 
carcinoma (<5 mm). 
57 instances (57.9%), whereas in cases of primary non-
invasive carcinoma, residual disease was seen in 17 of 26 
instances (65.4%). 
Residual invasive carcinoma would have been left in 
situ in 20 mastectomy specimens, accounting for 20 of 57 
83 
(35.1%) of the invasive cancers or 20 of 83 (24.1%) of the 
whole group. Residual noninvasive cancer was demonstrable in 
30 cases (36.1% of the whole group). In patients with primary 
ductal carcinoma, residual breast tumor was present in 44 
cases, representing 44 of 76 (57.9%) of these carcinomas, but 
in primary lobular carcinoma, residual tumor was seen in б of 
the 7 breasts(85.1%). Of 25 cases of primary ductal carcinoma 
in situ, residual ductal carcinoma in situ was found in 15 
(60%). 
In the total group of 96 patients bilateral breast cancer 
was present in 19 (Table 4). Six patients were treated 
previously because of invasive carcinoma. Since they bias the 
rate of bilaterality, they were excluded. The true incidence 
is still 13 of 90 (14.4%) of these patients. Simultaneous 
bilateral cancer occurred in 10 of 90 (11.1%) patients. 
Table 4: Status of the Contralateral Breast in 96 Patients 
with Ipsilateral Nonpalpable Breast Carcinoma 
Palpable 
5, IDC 
5, IDC 
3, ILC 
1, IDC 
Nonpalpable 
1, DCIS 
1, DCIS 
1, LCIS 
1, ILC 
1, LCIS 
Tota 
6 
10 
3 
Previous carcinoma 
Synchronous carcinoma 
Metachronous carcinoma 
DCIS = ductal carcinoma in situ; IDC = invasive ductal 
carcinoma; ILC = invasive lobular carcinoma; LCIS = lobular 
carcinoma in situ. 
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V.4 COMMENTS 
Studies on the multicentricity of breast tumors show a 
wide variation in freguency based on differences in case 
material, criteria for diagnosis of multicentricity and extent 
of sampling (3-8, 13-17). Overestimation of multicentricity 
occurs if the study population includes patients with locally 
advanced breast cancer or if any focus of cancer separate 
from, but in close proximity to the primary tumor is counted. 
The low incidence of multicentric cancer of 13.4 percent 
reported by Fisher et al in 1975 (17) is explained by the 
limited number of tissue blocks examined from each mastectomy 
specimen. Most investigators who have performed whole organ 
sectioning and correlated mammographie findings have 
demonstrated a much higher incidence (30 to 74 percent) 
(6,8,14). This applies to palpable breast carcinomas, but 
at first glance, one might expect similar figures for non-
palpable breast carcinoma since palpable and nonpalpable 
tumors differ only in epidemiologic lead time. As time 
passes, an impalpable tumor becomes palpable. This is true 
for invasive carcinoma because of continued growth. For non-
invasive carcinoma, the situation is more complicated, 
although there is now some evidence that in patients with 
ductal carcinoma in situ treated by biopsy only, ipsilateral 
invasive ductal carcinoma eventually develops in 28 to 67 
percent within 10 years (18,19). Among biopsy-treated patients 
with lobular carcinoma in situ, the frequency of subsequent 
invasive lobular carcinoma is 9 to 12 times the expected 
rate, occurring with equal frequency in the ipsilateral and 
contralateral breast after 15 to 20 years (19,20). 
In 1980, in a series of 53 mastectomies performed 
because of clinically occult breast carcinoma, Schwartz et 
al (9) demonstrated multicentricity in 21 mastectomy specimens 
(39.6 percent), and multicentric invasive foci were present 
in 4 (11.1 percent) of 36 specimensof occult invasive 
disease. Using the same criteria, we found an overall multi-
85 
centricity rate of 47 percent and distant multicentric 
invasive foci in 15 (26.3 percent) of the 57 évaluable occult 
invasive carcinomas. 
Nonpalpable breast carcinoma is clinically considered to 
be the earliest among the T. tumors and consequently a patient 
with such a tumor is an eligible candidate for breast 
conserving surgery and postoperative local radiotherapy. 
Thus, remaining invasive cancer foci may be responsible for 
short-term recurrences,and remaining noninvasive cancer foci 
may eventually develop into invasive cancer and cause long-
term recurrences. 
In our series, invasive tumor foci outside the quadrant 
of the primary tumor would have been left behind in about 
1 of 4 patients (15 of 57 patients, 26.3 percent) and 
residual invasive tumor outside the excisional biopsy cavity 
in about 1 of 3 patients (20 of 57 patients, 35.1 percent) 
with impalpable primary invasive cancer. Local irradiation 
should eradicate these invasive cancer cells and is apparently 
able to do so because, in the Milan trial, no difference in 
local recurrences within 5 years (including so-called second 
primary tumors) were shown between Τ.,Νρ. patients treated with 
Halsted mastectomy or with quadrantectomy, axillary dissection, 
and radiotherapy (1). 
Local recurrences after breast conserving surgery 
followed by radiotherapy for T. breast cancer have been 
reported between 2.3 and Θ.2 percent (21-24). Salvage 
mastectomy for recurrence in the breast still shows a 5 year 
survival rate of 67 percent (23). 
With regard to the occult noninvasive breast carcinomas, 
we found that multicentric noninvasive foci outside the 
primary quadrant were present in 46.2 percent of the primary 
noninvasive carcinomas and in 21.1 percent of the primary 
invasive carcinomas. If residual noninvasive carcinoma 
outside the excisional biopsy cavity is considered, then the 
multifocality rates increase to 65.4 percent and 22.8 percent, 
respectively. 
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Treatment of noninvasive breast carcinoma is still 
somewhat controversial. Because of its multifocal nature, 
total mastectomy would be the treatment of choice as it can 
cure these patients with almost 100 percent certainty. 
Moreover, a sampling error, that is, invasive foci in a 
quadrant remote from the in situ biopsy, has been demonstrated 
in 6 to 11 percent of patients (25,26). But in our series of 
26 évaluable breast specimens with occult noninvasive cancers, 
we did not encounter a sampling error. 
Analogous to small invasive carcinoma, conservation 
surgery and postoperative irradiation of the remaining 
breast is being performed for these usually occult non-
invasive tumors. However, the unjustifiable assumption has 
been made that in situ carcinoma has the same radiosensitivity 
as invasive carcinoma, which is probably not true because of 
the low mitotic activity of in situ carcinoma. A disadvantage 
is that the irradiated breast is less easily watched both 
clinically and mammographically and the diagnosis of local 
recurrence might be delayed. Radiotherapy might also 
contribute to carcinogenesis de novo. 
Because of the natural history of in situ carcinoma, 
when left alone after biopsy, it may take up to 10 years 
for ductal carcinoma in situ or 20 years and more for 
lobular carcinoma in situ, before invasive carcinoma becomes 
manifest (19,20). More study is required in regard to long-
term local recurrences after radiotherapy of in situ cancer 
of the breast. That is why we think there is still a place 
for total mastectomy in ductal carcinoma in situ, especially 
in the younger patient with a long life expectancy. Such a 
patient is also the best candidate for subsequent breast 
reconstruction. In lobular carcinoma in situ, the development 
of a new occurrence of invasive lobular carcinoma after 
excisional biopsy takes many years and the risk is bilateral 
(19,20). Therefore, these patients are kept under close 
supervision and regular follow-up examinations for the 
remainder of their lives (27). 
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The rate of bilaterality in the literature varies 
considerably depending on the characteristics of the study 
population (age, a personal or family history of breast 
cancer, and histologic type), extent of sampling, and duration 
of observation (28). The advent of mammography has contributed 
to the differentiation between primary and metastatic tumors 
and to earlier recognition, which has caused more tumors to 
be detected simultaneously (29). Liberal routine contralateral 
biopsy procedures also increase the detection rate of 
simultaneous bilaterality. Random sampling (a fifth of the 
mammary tissue in the upper outer quadrant), as well as mirror 
image biopsies, revealed simultaneous bilateral tumors in 
9.5 percent of these patients (30). However, not performing 
contralateral biopsies as a routine, and instead, only for 
mammographie indications , we found synchronous bilateral 
cancer in 11.1 percent of the patients. Considering this 
high yield,mammography of the contralateral side is, therefore, 
mandatory in the preoperative workup of patients scheduled 
for biopsy due to palpable lesions on the ipsilateral side. 
V.5 SUMMARY 
During a 9 year period, 300 consecutive women underwent 
breast biopsies solely because of nonpalpable, mammo-
graphically suspicious findings. One hundred clinically occult 
breast carcinomas were found, 65 of which were invasive and 
35 noninvasive. Eighty-three mastectomy specimens were 
évaluable for evidence of multifocal carcinoma in another 
quadrant of the breast or at a distance of 5 cm and residual 
cancer outside the excisional biopsy cavity. Multicentricity 
was present in 47 percent and residual tumor in 60 percent of 
the whole group. When only clinically occult invasive 
carcinomas were considered, other foci of invasive carcinoma 
were demonstrated in 26 percent of the patients and residual 
invasive cancer in 35 percent. The rate of bilaterality was 
14 percent, occurring synchronously in 11 percent of the 
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patients . 
Any therapeutic procedure for nonpalpable breast 
carcinoma, whether invasive or noninvasive ductal carcinoma, 
should be directed to the whole breast. Mammography of the 
contralateral side should be an integral part of the pre-
operative workup of patients with palpable lesions ipsi-
laterally. 
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VI.1 INTRODUCTION 
The concept of bilateralism in carcinoma of the breast is 
not new (1). Since the breast is a paired organ and, as cancer 
of this organ is frequently of multicentric origin, the 
development of simultaneous or subsequent independent 
malignancies on both sides is a well-established characteristic 
of breast carcinoma (2). 
In the past the discovery of the second primary was 
restricted to palpation and excision of abnormal masses (3-5). 
Alternative methods included routine 'random' biopsies of the 
upper outer quadrant or 'mirror-image' sampling of the 
opposite breast (6,7) and prophylactic contralateral mastectomy 
for patients at high risk (8-10). The advent of modern mammo-
graphy has made it possible to detect contralateral breast 
cancer selectively in its clinically occult or nonpalpable 
stage (11). 
The present study reviews our experience with bilateral 
breast cancer when routine mammography was used as a diagnostic 
adjunct in order to detect synchronous or metachronous (occult) 
breast carcinoma. 
VI.2 PATIENTS AND METHODS 
From 1970 through October,1985 a total of 824 patients with 
breast cancer have been treated at the Department of General 
Surgery, St. Radboud University Hospital, Nijmegen, The 
Netherlands. 
In 1970 modern mammographie equipment consisting of a 
molybdenum anode was installed and since then mammography has 
been used as an integral part of the preoperative work-up of 
(sub)clinical patients with primary breast cancer and of the 
regular follow-up of postmastectomy patients. 
Histological criteria for diagnosis of a second primary 
tumour included difference in histological types, demonstration 
of in situ change and different grade of differentiation. In 
94 
the absence of these criteria a second cancer was considered 
to be an independent primary when there was no evidence of 
local, regional or distant metastatic disease from the first 
primary. 
Synchronous carcinomas are defined as bilateral 
malignancies occurring within three months apart and meta-
chronous tumours as those occurring more than three months 
of each other. 
A breast was considered to harbour multicentric carcinoma 
if invasive and/or in situ carcinoma was found in a quadrant 
other than the one containing the primary tumour. In case of 
doubt or in retro-areolar locations, multicentricity was 
considered only if other cancer foci were at a distance of at 
least 5 cm (12). Thus, residual cancer after excisional biopsy 
or non-contiguous foci of cancer m the same quadrant, 
regardless of histology, are unicentnc for the purpose of 
this paper. 
This report concerns 55 patients with biopsy-proven 
bilateral breast cancer, discovered clinically and/or radio-
graphically. Routine contralateral biopsy was not practised, 
while prophylactic mastectomy was carried out only occasionally, 
resulting in two bilateral malignancies, which are included 
m this series. Complete follow-up data were available at the 
closure of this study in October,1985. 
VI.3 RESULTS 
The 55 patients with bilateral breast cancer represent 
6.7% of the total number of 824 patients with breast carcinoma 
treated during this 15-year period (Table 1). Twenty-three 
(=2.8%) had simultaneous primaries and 32 patients (=3.9%) 
subsequently developed a second primary carcinoma m the 
opposite breast. 
The mean age of the patients with synchronous tumours was 
60.3 years (range 43-76). In metachronous disease the mean 
age at the diagnosis of the first carcinoma was 52.5 years 
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Table 1: Some characteristics of 55 patients with bilateral 
primary breast cancer 
Feature Bilateral primary cancer 
Synchronous Metachronous 
1st 2nd 
Total 
Number of patients 
Percentage 
Mean age in years 
(range) 
Mean interval in months 
(range) 
Menopausal status 
- pre 
- post 
Fertility 
- nulliparous 
- parous 
Nursed 
Personal history of 
other malignancies 
Family history of 
breast cancer 
Family history of 
other malignancies 
23 
2.8 
60.3 
(43-76) 
0.2 
(0-3) 
6 
17 
6 
17 
14 
1 
6 
3 
52.5 
(34-79) 
32 
3.9 
57 
(37-1 
64. .8 
(8-289) 
15 
17 
8 
24 
22 
3 
10 
13 
8 
24 
.8 
83) 
55 
6.7 
14 
41 
36 
4 
16 
16 
Total number of breast cancers (unilateral + bilateral) is 
879; total number of breast cancer patients is 824 (=100%) 
(range 34-79), and at the second was 57.8 years (range 37-83). 
The younger age of the metachronous patients is reflected 
in the menopausal status: 15 or 46.9% were premenopausal 
during presentation of the first tumour,while only eight or 
25% had still their menses when the second tumour was detected, 
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similar to the synchronous group of whom six or 26.1% were 
still premenopausal. 
The mean interval between the two primaries was 64.8 
months (range 8-289). Twenty-four (=75%) of the second 
primary carcinomas occurred within five years following the 
first primary. 
A positive family history of breast cancer was found in 
six (=26.1%) of the patients with synchronous disease and m 
10 (=31.3%) of the patients in the metachronous group. 
If in simultaneous bilateral carcinoma the breast with 
the larger invasive lesion is considered to be the dominant 
side (11 χ left, 10 χ right and 2 χ equivocal) and in 
subsequent disease the breast in which the tumour first 
occurred (18 χ left and 14 χ right), then the left/right 
ratio is 1.21. 
Of 49 patients in whom the intra-breast location was 
known only 5 of the 21 patients with synchronous tumours 
(=23.8%) and 13 of the 28 patients with metachronous tumours 
(=46.4%) had 'mirror-image' tumours, 11 of them sited in the 
upper outer quadrant. 
Table 2 shows the relation between physical examination 
and mammography in the detection of bilateral breast cancer. 
Of the 100 breasts examined radiographically 89 had an 
abnormal mammogram: 50 with a palpable and 3 9 with a non-
Table 2: Correlation between clinical and radiographical 
findings in bilateral primary breast cancer 
Physical examination Mammogram 
Normal Abnormal None/Unknown Total 
Nonpalpable 2 3 9 0 41 
Palpable 9 50 10 69 
Total 11 89 10 110 
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palpable tumour. In 11 cases the malignant lesion was mammo­
graphically occult: 9 with a palpable and 2 with a non­
palpable tumour. The latter underwent a prophylactic mastectomy 
and both had lobular carcinoma in situ (= LCIS) on histo-
pathological examination. 
The nine palpable tumours with normal mammograms showed 
dense mastopathy in 7 cases (histopathology: 3 χ invasive 
lobular carcinoma, 2 χ tubular carcinoma, 1 χ comedo carcinoma 
and 1 χ invasive ductal carcinoma, not otherwise specified, 
and were radiographically completely normal in the remaining 
2 cases, both advanced invasive lobular carcinomas with 
pathological diameters of 60 and 90 mm, respectively. The mean 
age of the patients with mammographically occult tumours due to 
dense mastopathy was only 42.9 years (range 38-50). 
The stage of the tumour in the two groups of patients 
was analysed (Table 3). In the synchronous series, 5 or 22% 
had a nonpalpable tumour on the first side, but 15 or 65% on 
Table 3: T-stage of tumours in synchronous and metachronous 
bilateral primary breast cancer 
TO Tl T2 T3 T4 Tx 
Synchronous 
SI* 5 2 9 3 4 
S2 15 3 3 2 
Metachronous 
Ml* 5 6 13 3 3 2 
M2** 16 3 5 6 2 
51 and Ml indicate the first primary breast carcinoma found 
it* 
52 and M2 indicate the second or contralateral primary breast 
carcinoma found 
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Table 4: Analysis of failures to detect metachronous second 
primary breast cancer in its nonpalpable stage 
Follow-up 
Total 
number 
palpable 
Detected by 
physician/patient Pathology (No.) 
Mammographieally 
visible 
-interval carcinoma 
since last x-ray 
examination 
-observer's error 
comedo ca. (3) 
invasive ductal 
ca., NOS* (2) 
medullary ca. (1) 
mucinous ca. (1) 
DCIS (1) 
Paget's disease 
with invasive 
ductal ca. (1) 
Mammographically 
occult 
-masking effect of 
dense mastopathy 
-truly occult 
invasive lobular 
ca. (2) 
tubular ca. (1) 
invasive lobular 
ca. (1) 
Bad patient 
compliance invasive lobular 
ca. (1) 
papillary ca. (1) 
invasive ductal 
ca., NOS (1) 
NOS = not otherwise specified 
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Table 5: Histological types of 110 breast cancers in patients 
with bilateral disease 
Histology Clinically overt Clinically occult Total 
No. % No. % No. % 
Ductal 
- invasive, 
- scirrhous 
- tubular 
- DCIS 
Lobular 
- invasive 
- LCIS 
NOS* 36 
9 
2 
3 
15 
-
52. 
13, 
2. 
4, 
21. 
-
.2 
.0 
.9 
.3 
.7 
16 
2 
7 
7 
4 
5 
39.0 
4.9 
17.1 
17.1 
9.8 
12.2 
52 
11 
9 
10 
19 
5 
47.3 
10.0 
8.2 
9.1 
17.3 
4.5 
Others/Cancer, NOS* 4 5.8 - - 4 3 . 6 
Total 69 99.9 41 100.1 110 100.0 
NOS = not otherwise specified 
the contralateral side. Also in the metachronous cases the 
number of nonpalpable tumours increased from 5 or 16% on the 
first side to 16 or 50% on the second side. 
Thus 16 patients subsequently developed a palpable second 
breast cancer (Table 4): nine physician-discovered in the 
course of a regular follow-up and seven patient-discovered, 
of whom three had defaulted from follow-up. Of the 13 patients 
with palpable second primaries despite periodical check-ups 
nine had an abnormal mammogram (one radiographical density 
of 5 mm had been missed 18 months earlier), while the 
remaining four showed no abnormalities on the mammogram, 
apart from mastopathy thrice. Pathologically, three were 
invasive lobular carcinomas and one was a tubular carcinoma. 
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Table 6: Axillary status in synchronous and metachronous 
bilateral primary breast cancer 
No. of No. No. with Pos. nodes 
axillae évaluable pos. nodes % 
6 46.2 
3 27.3 
Synchronous 
SI* 
S2** 
Metachronous 
Ml* 
M2** 
23 
23 
32 
32 
13 
11 
20 
19 
7 35.0 
7 36.8 
Total 110 63 23 36.5 
51 and Ml indicate the first primary breast carcinoma found 
52 and M2 indicate the second or contralateral primary 
breast carcinoma found 
Two of the three defaulters had évaluable axillary nodes and 
both had multiple lymph node involvement. They were diagnosed 
at intervals of 4, Sand 24 years after treatment of the first 
primary carcinoma. 
The main histological types of the carcinomas in the 
55 bilateral breast cancer patients are recorded in Table 5. 
Invasive lobular carcinoma and scirrhous carcinoma are well 
represented in the clinically overt group. Tubular carcinoma, 
ductal carcinoma in situ (= DCIS) and LCIS are more prominent 
in the clinically occult group. 
A study was made of the incidence of metastasis to the 
axilla in synchronous and metachronous breast cancers (Table 6) 
In the synchronous group axillary involvement was noted in 
46.2% on the first or dominant side and in 27.3% on the 
opposite side. In the metachronous cases 3 5% had positive 
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Table 7: Correlation between clinical stage of the tumour and 
axillary involvement in bilateral primary breast 
cancer 
No. of No. No. with Pos. nodes 
axillae évaluable pos. nodes % 
Nonpalpable 41 26 3 11.5 
Palpable 69 37 20 54.1 
Total 110 63 23 36.5 
axillary lymph nodes on the first side and so had 36.8% 
also on the second side. 
Comparing clinically overt and clinically occult tumours 
54.1% of the évaluable palpable tumours showed axillary 
involvement, but only 11.5% of the évaluable nonpalpable 
tumours (Table 7) . 
Table 8 demonstrates the rate of multicentricity, which 
is higher m the synchronous than in the metachronous group: 
70.6% and 44.2%, respectively. The size of the primary tumour, 
whether palpable or nonpalpable, has little influence on 
multicentricity: 50.0% versus 61.1%. When looking at the 
main histological types invasive ductal carcinoma is multi-
centric in 44.6%, while invasive lobular carcinoma shows 
multicentricity in 73.3%. The rate of multicentricity is even 
higher (87.5%) m DCIS. The numbers of LCIS and others are 
too small to draw meaningful conclusions. 
The estimated survival according to the life-table 
method (13) of the bilateral breast cancer patients (all stages) 
is shown in Figure 1. Of the 23 patients with synchronous 
tumours four died from cancer and 19 were alive (of whom seven 
with disease) after a mean observation period of 69 months. 
Of the 32 patients with metachronous tumours nine died (seven 
from breast carcinoma and two from unrelated causes) and 23 
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Table 8: Multicentricity in bilateral primary breast cancer 
No.* No. Multi-
No. of No. uni- multicentric centricity 
breasts évaluable centric inv./noninv. rate (%) 
According to onset: 
- Synchronous 46 
- Metachronous 64 
According to 
physical findings: 
34 
52 
10 (RF3) 
29 (R=6) 
13 
11 
11 
12 
70.6 
44.2 
- Palpable 
- Nonpalpable 
According to 
histology: 
- Invasive ductal 
carcinoma 
- Invasive lobular 
carcinoma 
- nuctal carcincttia 
in situ 
- Lobular carcinctna 
in situ 
- Others 
69 
41 
72 
19 
10 
5 
4 
50 
36 
56 
15 
8 
4 
3 
25 
14 
31 
4 
1 
2 
1 
(R=6) 
(R=3) 
(RF=7) 
(R=2) 
18 
6 
17 
6 
_ 
_ 
1 
7 
16 
8 
5 
7 
2 
1 
50.0 
61.1 
44.6 
73.3 
87.5 
50.0 
66.6 
TOTAL 110 86 39 24 23 54.7 
In parentheses: R = Residual tumour in the same quadrant 
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Figure 1: Actuarial survival of patients with bilateral 
primary breast cancer 
I = Metachronous tumours - timed from first tumour 
II = Metachronous tumours - timed from second tumour 
III = Synchronous tumours 
percentage 
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32 64 96 128 160 192 224 256 288 320 
time (months) 
stayed alive (of whom three with disease) after a mean 
follow-up of 115 months. The survival of synchronous patients 
is 91% at 5 years and 74% at 10 years. In the metachronous 
group survival after the first diagnosis at 5 and 10 years is 
90% and 85%, respectively, and when measured from the second 
primary 84% and 59%, respectively. 
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VI.4 DISCUSSION 
Papers on bilateral breast cancer are difficult to 
compare because of differences in definition (primary or 
metastatic, synchronous or metachronous, pathological 
criteria of noninvasive carcinoma), composition of the various 
series (age, prognostic status, high-risk patients), diagnostic 
modality (clinical or mammographie signs, routine random 
biopsies and extent of sampling), duration and intensity of 
follow-up and analysis techniques (3,9,14,15). Bearing this 
in mind the reported incidence of bilateral metachronous 
disease is 4.3 - 8.2 second breast cancers per 1000 patient 
years (3,16-19). Bilateral synchronous mammary cancers are 
diagnosed in from 0.1 to 1.9 per cent of cases (3-5, 11, 19-25). 
Chaudary et al (18) have shown an almost fivefold 
increase of simultaneous bilateral disease till 2.4% after 
introduction of routine mammography in screening the opposite 
breast of women with ipsilateral breast carcinoma. By 
identifying subclinical lesions, more second cancers are 
placed into the synchronous category. Through the use of 
mammography the relative rate of synchronous cancers among 
bilateral breast carcinomas has risen to 26.9-50% (11,19,26), 
which is comparable with the high proportion of synchronous 
carcinomas (41.8%) that we found. In the course of time this 
percentage will fall to about 30% due to the steady 
development of metachronous tumours at a rate of approximately 
1% per year per woman at risk (3,18). 
In series employing contralateral biopsies the occurrence 
rate of simultaneous tumours varies between 2 and 12.7%, 
depending on how extensively has been sampled by the surgeon 
and how thoroughly the sections have been studied by the 
pathologist (7-9,27-31). However, many of these were non-
invasive carcinomas, especially LCIS, and its fate and 
management remain a source of discussion (32,33). Urban et 
al (7) reported on 301 random opposite breast biopsies, truly 
occult in the absence of any physical or mammographical signs, 
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and diagnosed 23 carcinomas (7.6%): 5 χ infiltrating and 18 χ 
noninfiltrating. Recently, Wanebo et al (34) described their 
results with elective contralateral biopsies: 13 of 62 patients 
(21%) had simultaneous cancer in the second breast. Six, 
however, were either palpable (two) or had a suspicious mammo­
gram (four), so the true incidence of clinically and radio-
graphically occult contralateral breast carcinoma is 11.3% 
(7 out of 62 patients). Ten out of 13 were noninvasive: 
6 χ LCIS and 4 χ DCIS. 
In autopsy series the reported incidence is 10-21% (35-37). 
Those percentages of bilateral breast cancer,exceeding 8 to 10% 
observed clinically, suggest that some second primaries either 
regress or do not develop into invasive cancers during the 
patient's life-time. 
If a woman has had breast cancer on one side, she has a 
5-8 times greater risk of developing a second primary on the 
other side than women in the general population have to 
develop cancer in their first breast (3,4,18,36). Or in the 
words of Foote and Stewart's (38) much cited quotation: 
'The one most common "precancerous" lesion of the left breast 
is a cancer of the right breast and vice versa'. This risk of 
the remaining breast is not augmented by previous radiotherapy 
(39,40) . 
We believe that follow-up of unilateral breast cancer 
patients, who belong to the population at the highest risk, 
is valuable because in our patients 29 out of 55 synchronous or 
metachronous malignancies (=52.7%) of the opposite breast 
were detected by mammographie means alone, excluding the two 
patients (=3.6%) who underwent a prophylactic mastectomy. The 
following reasons may explain why mammography failed to discover 
the malignancy in its nonpalpable or subclinical stage: 
first, because of fast growing interval cancers; second, 
because of the masking effect of dense mastopathy; third, 
because of lobular carcinoma, both infiltrating and in situ, 
which are difficult to visualize radiographically; fourth, 
because of technical or observer's errors (41,42). These 
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reasons, leaving apart bad patient compliance in 3 cases, have 
probably biased the rate of positive axillary nodes of the 
second primary tumours in our metachronous group, despite the 
low rate of positive nodes (11.5%) in the nonpalpable tumours. 
Moreover, any radiographical miss in the patients with 
synchronous bilateral breast carcinoma will contribute to the 
bias of the figures in the metachronous group. Survival of 
patients with synchronous bilateral primary breast cancer 
has been reported to be poor (5,19,24,39,43,44), while others 
(31,40) found no unfavourable difference in prognosis when 
compared with unilateral breast cancer patients or with 
patients in the metachronous group. 
In metachronous breast cancer patients the survival 
measured from the time of presentation of the first tumour 
is usually better than the survival of patients with uni-
lateral disease because of selection bias: only those surviving 
the first tumour, do live long enough to stand a chance to 
develop another primary in the opposite breast (19,34,44,45). 
Although a contralateral prophylactic mastectomy, 
routinely (46) or for patients at high risk (8,9), has been 
advocated in the past,it is obvious that this would result in 
many unnecessary mastectomies and the anticipated benefits 
would be minimal. 
Slack et al (16) calculated a maximum gain of 0.8% in the 
relative survival of all women developing a second breast 
cancer in the first five years at the expense of 98% futile 
mastectomies. 
We believe that a watchful waiting policy is the strategy 
of choice now mammography has provided us with a useful tool 
for screening the remaining breast. Breast x-ray (low-dose 
mammography) should be performed annually (47). However, any 
palpable lump, regardless of mammogram, must be examined 
histologically, except for cysts. 
In case of a dense parenchymal pattern rendering mammo-
graphy less efficient in detecting carcinomas, an elective 
contralateral biopsy could be considered. The technique 
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involves removal of a wedge-shaped piece of tissue from the 
upper outer quadrant including a wedge from the retro-
mamillary tissue via a circumareolar incision (31). This is 
particularly advisable in case of LCIS or LCIS coexisting 
with invasive ductal carcinoma or invasive lobular carcinoma 
(2), and DCIS (48), because of their tendency of multi­
centricity and bilaterality. 
VI.5 SUMMARY 
The significance of mammography in the detection of 
contralateral primary breast cancer was evaluated in 55 
patients with bilateral breast disease. Fifteen of 23 patients 
(=65%) in the synchronous group and 16 of 32 patients (=50%) 
in the metachronous group had clinically occult carcinoma 
in the opposite breast. Excluding the two malignancies 
discovered by prophylactic mastectomy, mammography alone 
was responsible for the detection of 29 nonpalpable, contra­
lateral breast carcinomas (=52.7%). The whole series of 110 
malignant breasts comprised 41 nonpalpable carcinomas, of 
which 12 were noninvasive (7 χ DCIS and 5 χ LCIS) and the 
remaining 29 were invasive carcinomas, either ductal of 
various types (25 x) or lobular (4 x). With regard to the 
évaluable axillary nodes, 20 of 37 palpable breast cancers 
(=54.1%) and only 3 of 26 nonpalpable breast carcinomas 
(=11.5%) had positive lymph nodes. The multicentricity rate 
was particularly high in synchronous tumours (=70.6%), and 
in invasive lobular (=73.3%) and noninvasive (=75%) 
carcinomas. The favourable 5- and 10-year survival of 
patients, both in synchronous and metachronous bilateral 
primary breast cancer, justify that they be treated with 
aggressive optimism. 
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VII.l INTRODUCTION 
When the concept of minimal breast cancer (MBC) was first 
proposed in 1971 (1), it was intended, entirely on hypothetical 
grounds, to delineate a certain subgroup of breast carcinoma 
patients with an extremely favourable prognosis. According to 
the original definition MBC included lobular carcinoma in situ 
(LCIS), ductal carcinoma in situ (DCIS) and minimally invasive 
carcinoma (MIC), either lobular or ductal, not exceeding 5 mm 
in diameter. Based on this it was assumed that axillary 
lymph node involvement would occur in less than 10% and it 
was predicted that the long-term survival rate would be 
approximately 95% (2). 
Only a few authors have so far published their results 
with regard to axillary status and long-term follow-up (3-6). 
Their results, summarized recently (7), do support the 
validity of the original concept showing a 5.5% rate of 
positive axillary nodes and a disease-free survival of well 
over 96%. The vast majority of the lesions in the above 
mentioned reports was self-discovered as a palpable mass. 
The favourable outcome of MBC, however, has been challenged 
by the large inter-institutional survey of the American 
College of Surgeons (8). Also controversy exists with regard 
to the upper limit of MIC of either lobular or ductal type 
whose greatest diameter has been extended and may be equal 
to, but does not exceed 1 cm as defined by the American 
College of Surgeons (8) or may be less than 1 cm in greatest 
diameter as recommended by the American Cancer Society and 
in use by the Breast Cancer Detection Demonstration Projects 
of the National Cancer Institute (9). 
Because of the various definitions of MBC used, the present 
study from one single institution has the following objectives: 
- to present our experience with a large series of clinically 
occult breast cancers in relation to residual tumour after 
excisional biopsy. 
- to compare the nodal status of nonpalpable, noninvasive 
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tumours, MIC of 5 mm or less, 6 to 10 mm and invasive 
carcinomas larger than 10 mm. 
- to analyse the long-term survival of nonpalpable breast 
carcinomas when divided according to nodal status and size 
of the tumour: noninvasive and MIC with the upper limit at 
5 or at 10 mm. 
VII.2 PATIENTS AND METHODS 
In 1970 modern mammographie equipment has been installed 
at the St. Radboud University Hospital, Nijmegen, The 
Netherlands, and since then clinically occult, only radio-
graphically visible breast carcinomas have been diagnosed with 
increasing frequency. 
With effect from 1st January,1975 a population screening 
programme has been going on in the city of Nijmegen aimed at 
the whole female population over 35 years of age and patients 
with suspicious findings were referred to the surgical 
department of one of the two hospitals serving the city. Thus 
our patient material includes a part of the population 
screenees. 
When it was indicated that a biopsy was needed, the non-
palpable, mammographie abnormality was localized and excised 
by one of the methods described by us previously (10) . Because 
of the supposedly small sizes of the nonpalpable mammographie 
abnormalies, an excisional biopsy had always been aimed at. 
Specimen radiography was considered to be mandatory. 
Frozen-section examination was left to the discretion of the 
pathologist who used to judge it feasible in nonpalpable 
masses of 5 mm or more, but was inclined to defer his final 
diagnosis until the paraffin sections were ready in case of 
clustered microcalcifications only and of nonpalpable masses 
of less than 5 mm (11). 
Since 1978 all mastectomy specimens were examined using 
Egan's technique of correlating radiographical and histo-
pathological findings (12-14). Our data before 1978 are based 
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on the routine pathology reports. In case of invasive breast 
carcinoma the pathological diameter was used primarily. Where 
this was not available in 12 cases (7.8%) we had to resort to 
the radiograpnical measurements. Residual tumour was defined by 
us as any ductal or lobular carcinomatous tissue, either 
invasive or noninvasive, left behind outside the biopsy cavity 
within the mastectomy specimen. 
The treatment modality has changed in the course of time. 
Before 1977 radical mastectomy was the usual treatment for 
lateral carcinomas, while centrally and medially seated 
tumours were treated by simple total mastectomy combined with 
postoperative irradiation of the regional lymph nodes. Since 
1977 modified radical mastectomy has been the treatment of 
choice for both lateral and central/medial tumours. This 
applied to invasive carcinomas, whether ductal or lobular, and 
noninvasive DCIS. Patients with LCIS were kept under close 
observation for the remainder of their lives. 
At the closure of this study in March, 1986, a 100% 
follow-up has been attained. However, for the sake of the 
survival of the nonpalpable breast cancers all patients with 
prior, synchronous or metachronous, contralateral breast 
malignancies, which were palpable, have been excluded. But 
patients with bilateral synchronous or metachronous non-
palpable tumours are included. 
The estimated survival was calculated according to the 
life-table method (15). For comparison of the survival rates 
Gehan-Mantel's modification of the Wilcoxon test was used 
(16,17) . 
VII.3 RESULTS 
From 1st January, 1971, through February, 1986, 153 non-
palpable breast carcinomas have been treated at the department 
of general surgery of the St. Radboud University Hospital. 
This represents 17.2% of the total of 889 breast cancers 
operated upon during this 15-year period. 
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Sixty-eight cancers were found as a result of population 
screening while the remaining 85 cancers were detected at the 
surgical out-patients' department through individual screening: 
annual mammogram after prior contralateral mastectomy 19 x, 
mastodynia 16 x, mammographie control because of histologically 
proven 'premalignant' lesion 16 x, synchronous cancer of the 
opposite breast 8 x, nipple discharge 7 x, unsuspicious palpable 
mass elsewhere in the same breast 5 x, palpable axillary mass 
4 x, positive family history 3 x, follow-up of an irradiated 
breast 1 x, pathological fracture of the sternum 1 χ and no 
apparent reason 5 x. 
Clusters of microcalcifications were the most frequent 
mammographie lesion (74=48.4%), followed by stellate shaped 
masses (44=28.7%), masses with microcalcifications (17=11.1%), 
circumscribed or nodular masses (13=8.5%), disturbed 
architecture (2=1.3%) and, at last, no abnormalities (3=2.0%). 
The mean age of the patients was 56.4 years (range 37-78). 
Only three patients were younger than 4 0 years: one patient 
of 37 years had LCIS, another of 38 years had DCIS and the 
third patient was also 38 years of age and she had a tubular 
carcinoma with a diameter of 7 mm. 
The several surgical treatment modalities are summarized 
in Table 1 . Please note that excisional biopsy for invasive 
breast cancer (5 x) was practised only in very special circum­
stances: distant metastases (1 x), local recurrence in a post-
irradiated breast because of a N 3 tumour in the past (1 χ), 
synchronously an inoperable T 4 tumour in the opposite breast 
(1 x) and contralateral invasive Tj tumours in elderly people 
(2 x). 
They all had additive radiotherapeutical and/or hormonal/ 
chemotherapeutical treatment. Excisional biopsy for noninvasive 
DCIS (5 χ) was also limited to exceptional cases: diagnosis 
made later on after revision of the pathology slide (1 χ), age 
over 70 years (2 χ), patient's refusal of further treatment 
(1 x) and one patient who had breast conserving treatment for 
a contralateral invasive T, tumour in the past (1 x). 
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Table 1: Treatment modalities of nonpalpable breast cancer 
•k dgk 
Type of surgery Invasive Noninvasive Others Total 
carcinccna carcinana 
>10 imi 6-10 mn <5 іші DCIS LCIS 
15 
Radical 
mastectony 
Modified 
radical 
mastectony 
Simple total 
mastectaiy 
Subcutaneous 
mastectomy 
Lumpectomy and 
axillary 
dissection 
Excisional 
biopsy 
7 
30 
7 
-
6 
3 
21 8 23 2 84 
22 
20 
irrespective of adjuvant/palliative radiotherapy and/or chanotherapy 
one case of non-Hodgkm ' s lymphona and one basal ce l l carcinana 
DCIS = ductal carcirona in s i tu 
LCIS = lobular carcmoma in s i tu 
Table 2 n o t e s t h e i n c i d e n c e of r e s i d u a l tumour o u t s i d e t h e 
b i o p s y c a v i t y i n t h e 118 mastectomy specimens f u l l y é v a l u a b l e 
h i s t o l o g i c a l l y a f t e r p r i o r ' e x c i s i o n a l ' b i o p s y . The o v e r a l l 
i n c i d e n c e of r e s i d u a l tumour, i n c l u d i n g LCIS,was 76 /118 , or 
64.4%. The r a t e of r e s i d u a l carcinoma i s t h e same in t h e 
nonpa lpab l e i n v a s i v e a s w e l l m t h e nonpa lpab le non invas ive 
g roup: 64.0% v e r s u s 65.6%. When look ing a t t h e c l i n i c a l l y 
o c c u l t i n v a s i v e b r e a s t c a n c e r s a l o n e , then i n v a s i v e cance rous 
t i s s u e would have been l e f t behind in 34 of 86 é v a l u a b l e 
mastectomy spec imens , or 3 9.5%. 
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T a b l e 2 : R e s i d u a l t u m o u r s o u t s i d e t h e b i o p s y c a v i t y a f t e r 
' e x c i s i o n a l ' b i o p s y b e c a u s e of c l i n i c a l l y o c c u l t 
b r e a s t c a n c e r 
Tota l No. of No. wi th 
No. 
Invasive 
duc ta l o r lobula r 
carcinona >10 itm 53 
Invasive 
ductal or lobular 
carcinona 6-10 ntn 29 
Invasive 
duc ta l or lobu la r 
carcinona <5 nm 18 
mastectony r e s i d u a l 
specimens tumour 
évaluable 
43 
27 
16 
Inv. Noninv. 
DCIS LCIS 
23 
% with 
r e s i d u a l 
tumour 
67.4 
51.9 
75 
Tota l invasive 
carcinona 100 86 34 15 64.0 
DCIS 
LCIS 
39 
12 
30 
2 
0 19 0 63.3 
0 0 2 100 
Total noninvasive 
carcinona 51 32 0 19 2 65.6 
Others 0 0 0 
Grand t o t a l 153 118 34 34 8 64.4 
The a x i l l a r y lymph n o d e i n v o l v e m e n t o f t h e d i f f e r e n t 
s u b g r o u p s of n o n p a l p a b l e b r e a s t c a n c e r s i s p r e s e n t e d i n T a b l e 
3 . One p a t i e n t h a d p r i m a r i l y e v i d e n c e of d i s t a n t m e t a s t a s e s 
( p a t h o l o g i c a l f r a c t u r e o f t h e s t e r n u m a n d bone mar row 
i n v o l v e m e n t a s p r o v e n by a n e e d l e a s p i r a t i o n b i o p s y of t h e 
121 
Table 3: A x i l l a r y s t a t u s of p a t i e n t s w i t h c l i n i c a l l y o c c u l t 
b r e a s t c a n c e r 
Invasive ductal or 
lobular carcincma 
>10 іші 
Total 
No. 
No. of 
axillas 
évaluable 
No. with 
positive 
nodes 
% with 
positive 
nodes 
53 44 13 29.5 
Invasive ductal or 
lobular carcincma 
6-10 im 29 24 12.5 
Invasive duc ta l o r 
lobu la r ca rc i rona 
<5 irai 18 13 7.7 
DCIS 
LCIS 
39 
12 
25 
Others 
TOTAL 153 108 17 15.7 
* includes one patient with distant metastases 
i l i a c c r e s t ) . The o t h e r 16 p a t i e n t s had s e c o n d a r i e s in t h e 
a x i l l a : one p a t i e n t had a p o s i t i v e i n f r a c l a v i c u l a r a p i c a l 
b iopsy (pN,) , t h e r e was one p a t i e n t w i t h a pN-, a x i l l a r y 
tumour and one p a t i e n t w i th a pN., a x i l l a r y tumour. In t h e 
remain ing 13 p a t i e n t s a d e t a i l e d a x i l l a r y p i c t u r e was known: 
4 x 1 p o s i t i v e lymph node , 3 x 2 p o s i t i v e nodes , 4 x 3 and 
2 x 4 p o s i t i v e nodes (range of nodes examined 1 2 - 4 2 ) . The non-
i n v a s i v e b r e a s t c a n c e r s d id not show any secondary sp read i n t o 
t h e a x i l l a r y lymph nodes , but t h e i n v a s i v e b r e a s t c a n c e r s 
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Table 4: Clinical T-stage of tumours of the contralateral 
breast in ipsilateral nonpalpable breast cancer 
T 0 TJ^  T 2 T 3 T 4 Τ χ Total 
Prior carcinoma 0 4 9 2 1 2 18 
Synchronous carcinoma 5 2 5 2 1 0 15 
Metachronous carcinoma 4 0 0 1 1 0 6 
Total 9 6 14 5 3 2 39 
showed with increasing diameter more regional lymph node 
involvement: 7.7% in the invasive cancers equal to or smaller 
than 5 mm, 12.5% in the invasive cancers of between 6 and 10 mm 
and 29.5% in the invasive cancers of over 10 mm. 
Table 4 shows the number of bilateral tumours in this 
series of 153 nonpalpable breast cancers. In order to avoid 
bias all 30 patients with a prior, synchronous and metachronous 
contralateral breast carcinoma, which was palpable, have been 
excluded for actuarial calculation of the disease-free survival. 
Also the patient with the basal cell carcinoma which is not a 
breast carcinoma strictly speaking and the patient with the 
local recurrence in the irradiated breast have been excluded. 
This leaves 121 évaluable, nonpalpable breast cancers, nine of 
which are bilateral. 
The current status of the patients as per 1st March, 1986, 
is demonstrated in Table 5, which is self-explanatory. 
As depicted in Figure 1 the patients with negative 
axillary nodes exhibit a significant better (p < 0.001) disease-
free survival than patients with positive nodes: 95.7% and 
76.0%, respectively. The disease-free survival also differs 
significantly (p < 0.01) in patients with noninvasive carcinoma 
and MIC < 10 mm (97.7%), when compared with invasive tumours 
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Table 5: Current status of patients with 153 nonpalpable 
breast cancers 
Feature Total no. NED AWD DOC DWD 
Inclusions 121 109 2 5 5 
Exclusions 32 23 4 3 2 
* Closure of the study: Ist March, 1986 
100% follow-up 
Mean observation period 68.9 months (range 1-174) 
Abbreviations: NED = No Evidence of Disease 
AWD = Alive With Disease 
DOC = Dead of Other Cause 
DWD = Dead With Disease 
>10 mm (77.3%), as shown in Figure 2. However, there is no 
significant difference (p = 0.06) in disease-free survival, 
when noninvasive carcinoma and MIC £ 5 mm are compared with 
invasive tumours > 5 mm. 
The overall survival was significantly higher (p < 0.0001) 
m patients with negative axillary nodes than in the group of 
patients with positive nodes: 96.7% versus 72.2%, respectively 
(see Figure 3). At last, the overall survival achieved 
statistical significance (p < 0.03) and is better in non-
invasive carcinoma and MIC £ 10 mm (96.9%) than in invasive 
tumours measuring over 10 mm (83.6%), as demonstrated in 
Figure 4. When the upper limit for invasive cancer is drawn 
at 5 mm, however, then there is no statistical difference 
(p = 0.14) in overall survival between noninvasive carcinoma 
and MIC £ 5 mm in comparison with invasive carcinoma > 5 mm. 
No statistically significant differences have been found 
in disease-free survival (p = 0.26) and overall survival 
(p = 0.42) between pre- and postmenopausal women. Furthermore, 
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β lymphpodes negative 
• lymphnode* positive 
• lympnnod» unknown 
6 0 120 180 
disease free survival (months) 
Figure 1: 
Disease-free survival in non­
palpable breast cancer 
according to axillary nodal 
status 
percentage 
\ 
0 6 0 120 180 
disease free survival [months) 
Figure 2: 
Disease-free survival in non­
palpable breast cancer 
according to tumour size 
I = noninvasive carcinoma 
+ minimally invasive 
carcinoma £ 10 mm 
II = invasive carcinoma > 10 mm 
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percentage 
100 
Γ 
' lymph nodes negative 
• lymphnodes positive 
lymphnodw unknown 
120 180 
survival (months) 
Figure 3: 
Survival in nonpalpable 
breast cancer according to 
axillary nodal status 
percentage -
^ 
0 6 0 120 180 
survival (months) 
Figure 4 : 
Survival in nonpalpable breast 
cancer according to tumour size 
I = noninvasive carcinoma 
+ minimally invasive 
carcinoma £ 10 mm 
II = invasive carcinoma > 10 mm 
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patients with nonpalpable breast cancer originating from the 
population screening programme had no better disease-free 
survival (p = 0.31) or overall survival (p = 0.10) than 
patients who were detected as a result of individual screening. 
Noninvasive DCIS and LCIS were not associated with 
positive axillary nodes and the disease-free survival was 
100%, after a mean observation period of 66.1 months (range 
4-174). 
VII.4 DISCUSSION 
First of all we should reconsider some definitions in 
respect of favourable phases of breast cancer. 
With 'early' is commonly meant any carcinoma not 
associated with axillary lymph node metastasis, i.e. mainly 
stage Ι (Τ.Νρ,Μρ.) disease, but also a few in stages II 
(T-N-Mf.) and III Α (Τ,Ν.ΙΟ according to the American Joint 
Committee on Cancer Classification (18). 
'Minimal' breast cancer was originally designated to 
include DCIS, LCIS and MIC £ 5 mm (1,4,5). Others limited 
themselves to DCIS and MIC of the ductal type only up to and 
including 5 mm (6) or extended the definition to all invasive 
cancers 1 cm or less in diameter presenting in the outer half 
of the breast only and with clinically no evidence of axillary 
lymph node metastases and also including some low-grade 
infiltrating cancers like adenoid cystic carcinoma, colloid 
carcinoma, intracystic papillary carcinoma, tubular carcinoma 
and malignant cystosarcoma phyllodes (3). In recent years the 
American College of Surgeons in their breast cancer surveys 
redefined MBC as any DCIS, LCIS or any invasive carcinoma of 
either pathological type measuring 1 cm or less (8), while 
the Breast Cancer Detection Demonstration Projects included 
the same category only when the invasive lesion was less than 
1 cm in its greatest diameter (9). 
The term 'occult' or 'subclinical' breast cancer is 
reserved for nonpalpable cancers which are usually demonstrable 
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only by mammographie means. In the absence of any roentgenologic 
abnormality in the breast occult breast cancer may also be a 
serendipitous finding when performing excision of breast 
tissues on other grounds. 
So occult cancer may not be minimal, if over 0.5 or 1 cm, 
when buried deeply within large or nodular breasts, although 
the majority of the occult cancers will be minimal. Depending 
on which definition of MBC is used, 69/151 or 45.7% of our 
series was in situ carcinoma or MIC £ 5 mm, and 98/151 or 
64.9% was in the category of in situ carcinoma or MIC £ 10 mm. 
Most occult cancers will also be early, but positive 
axillary lymph nodes do occur. Again, depending on the 
definition, the rate of positive axillary lymph nodes is 
1/40 or 2.5%, if we consider the in situ carcinomas and MIC 
<_ 5 mm, and 4/64 or 6.3%, if m situ carcinomas and MIC £ 10 mm 
are counted. Conversely, many early cancers are too large to 
fit in the diagnosis clinically occult or subclinical. 
Through the use of mammography in population and individual 
screening an ever increasing number of nonpalpable breast 
cancers is emerging, representing a special subgroup of 
clinically occult cancers amongst the T. tumours. The occult 
tumours differ from those, that surfaced clinically as a 
palpable mass, through their lead time, which is estimated 
at approximately three years (19,20) . Also length bias plays 
a role because fast growing interval cancers, which become 
palpable between two roentgenologic screening examinations, 
are missed mammographically (21,22). Schwartz et al (23) have 
proposed that for staging of nonpalpable breast cancer the 
mammographie size of the mass be considered with the addition 
of the notation that it was discovered by mammography, for 
instance Tj. . , T-, « etc. The nonpalpable breast cancers 
detected by clustered microcalcifications and areas of 
distorted architecture without a roentgenologic mass should 
then be staged T
n
, . . Similarly, Τ could be modified into 
^ 0(m) J is 
Τ , , , if it refers to an occult DCIS or LCIS detected is(m) 
mammographically. 
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The prognosis of clinically occult breast cancers has 
recently been reported to be extremely good with long-term 
survival rates of 95% (24) and 96.8% (25). 
Our actuarial estimates of 10-year survival of non-
invasive and small invasive carcinomas £ 10 mm reaches 
96.9% and is well comparable with the aforementioned results. 
The indicator of this good prognosis is the low rate of 
positive axillary lymph nodes (6.3%) amongst these tumours. 
This is illustrated by the fact that node-negative patients 
with occult tumours do have a 96.7% long-term actuarial 
survival rate. 
On the other hand, occult invasive carcinomas > 10 mm 
show a 29.5% rate of positive axillary lymph nodes and are 
associated with a less favourable long-term actuarial survival 
rate of 83.6%. This is reflected in the finding that node-
positive patients, whose tumours have been detected by mammo-
graphy alone, have a long-term survival of only 72.2%. 
This means that nodal status (negative vs. positive) 
and size of the invasive tumour (equal to or less than 10 mm 
vs. over 10 mm) are both strong determinants of prognosis in 
clinically occult breast cancer. As a result of this we concur 
with the American College of Surgeons' definition (8) that the 
upper limit of MIC is at 10 mm and that MBC includes, apart 
from noninvasive DCIS and LCIS, all invasive lesions of 10 mm 
or less. 
The prognosis was not influenced by the fact whether the 
patient was detected by population or individual screening 
which means that the mammogram itself has a certain predictive 
value per se. 
Contrary to others (25), who found better survival in 
women over 50 years of age with clinically occult breast 
cancer, we did not find any difference in relation to menopausal 
status. 
The high rate (64%) of residual tumour m nonpalpable 
breast cancer implies that the whole breast must be subject of 
treatment, whether surgically or radiotherapeutically. This 
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has been discussed by us already in detail elsewhere (14). The 
only exceptions are patients with noninvasive LCIS who are kept 
under periodical follow-up examinations for the rest of their 
lives (26). 
Then remains the question whether or not an axillary 
dissection should be done. Though positive axillary nodes 
have been described in association with DCIS (27,28), we did 
not encounter any axillary lymph node involvement in 27 
fully évaluable specimens of axillas in patients with non-
invasive carcinoma. That is why we think that axillary 
dissection in noninvasive carcinoma is unwarranted, provided 
the whole breast is thoroughly examined histopathologically 
in order to rule out hidden foci of invasive cancer. In 
invasive cancer, however, the rate of positive axillary 
lymph nodes in patients with invasive carcinoma £ 10 mm is 
low (4/37 or 10.8%), albeit not insignificant. Of the four 
patients with axillary involvement in this category one 
patient had one positive lymph node at level I, two patients 
had three positive nodes at level II and another one had one 
positive node at level III. All are disease-free alive after 
157, 44, 7 and 2 months, respectively. We, therefore, believe 
that the removal of only the basal, level I nodes in invasive 
cancer _< 10 mm is insufficient locoregional treatment and a 
complete axillary dissection should be performed. Similarly, 
invasive breast cancer > 10 mm, with axillary metastases at 
a rate of 29.5%, must be treated by full axillary dissection. 
Although possible lead time and length bias (21) should 
be taken into account, the above reported long-term recurrence 
and survival results of nonpalpable breast cancer from one 
single institution show an excellent prognosis and support 
the view derived from various population screening programmes 
(29-31) that secondary prevention of breast cancer can save 
more lives. 
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VI I.5 SUMMARY 
One hundred and fifty-three nonpalpable breast cancers 
have been diagnosed and treated since 1971, including 100 
invasive carcinomas, 3 9 in situ ductal carcinomas and 12 
lobular carcinomas in situ. Of the 100 clinically occult 
invasive carcinomas, 53 had pathologic diameters of more than 
10 mm, 29 had a size of between 6 and 10 mm, and 18 were 
tumours of 5 mm or less. 
Residual tumour outside the 'excisional' biopsy cavity 
was encountered in 64.4% of the 118 fully évaluable mastectomy 
specimens. Invasive residual tumour would have been left 
behind in 34 of 86 (39.5%) mastectomy specimens. 
No patient with m situ carcinoma had evidence of 
axillary lymph node metastases in 27 specimens studied. 
Invasive carcinoma, however, showed axillary lymph node 
involvement m 7.7% when the size of the primary tumour was not 
more than 5 mm, in 12.5% when the size was between 6 and 10 mm, 
and in 2 9.5% when the primary tumour was over 10 mm in diameter. 
There was a significantly better disease-free (p<0.001) 
and overall survival (p<0.0001) in patients with clinically 
occult breast cancer with negative axillary nodes (95.7% and 
96.7%, respectively) than in patients with positive axillary 
nodes (76.0% and 72.2%, respectively). If the upper limit of 
occult invasive carcinoma was drawn at 10 mm, then statistically 
significant differences in disease-free (p<0.01) and overall 
survival rates (p<0.03) were achieved for occult minimal 
breast cancer (noninvasive carcinoma + invasive carcinoma £10 mm) 
(97.7% and 96.9%, respectively) versus occult invasive carcinoma 
>10 mm (77.3% and 83.6%, respectively). However, if the upper 
limit of occult invasive carcinoma was chosen at 5 mm, then no 
statistically significant differences (p>0.05) could be obtained 
in disease-free and overall survival rates between occult 
minimal breast cancer (noninvasive carcinoma + invasive 
carcinoma <5 mm) and occult invasive carcinoma >5 mm. Also 
there was no significant difference (p>0.05) in disease-free 
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and overall survival between pre- and postmenopausal women 
with clinically occult breast cancer. 
In conclusion, the validity of the concept of minimal 
breast cancer has been re-enforced. However, the results of 
this study suggest that the upper limit of the original 
definition of minimal breast cancer is too narrow and should 
be extended, so that, apart from the noninvasive tumours 
regardless of their size, all invasive tumours up to and 
including 10 mm in greatest diameter should be regarded as 
minimal breast cancers. 
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SAMENVATTING 
Borstkanker bi] de vrouw is een maatschappelijk belang-
rijk gezondheidsprobleem m Nederland, dat één op de twaalf 
vrouwen in de loop van hun leven zal treffen. Aangezien de 
lange-termijn overleving na therapie al vele jaren vastligt 
op ongeveer 60% en afhangt van het klinische stadium waarin de 
patiente zich voor het eerst met een palpabele tumor presenteert, 
is alle hoop op verbetering van de prognose gevestigd op 
vroege opsporing, dat wil zeggen ontdekking in een stadium 
wanneer de tumor nog niet palpabel is. De beste techniek om 
borstkanker in zo een vroeg, nog met-palpabel stadium op te 
sporen, is het mammografisch onderzoek. Recente gegevens uit 
enkele bevolkingsonderzoeken, met behulp van mammografie, wijzen 
er inderdaad op dat de prognose door vroege opsporing kan ver-
beteren. De clinicus-practicus wordt in toenemende mate gecon-
fronteerd met met-palpabele, slechts röntgenologisch zicht-
bare mamma-afwijkingen. Dit proefschrift tracht enkele aspecten 
hiervan te verhelderen, gezien vanuit het standpunt van de 
chirurg. 
Het localiseren en excideren van met-palpabele borst-
afwijkingen wordt geëvalueerd in hoofdstuk I. 
Er worden drie methoden om met-palpabele, maar mammo-
grafisch verdachte borstafwijkingen te excideren met elkaar 
vergeleken: (1) 'blinde' methode, gebruik makend van mammo-
grafische coördinaten, (2) preoperatieve localisatie met behulp 
van de naald van Frank, en (3) localisatie met de naald van 
Frank via een compressieplaat met multipele gaatjes. In onge-
veer 80% gelukte het, met welke methode dan ook, om de bewuste 
röntgenologische afwijking bij de eerste biopsiepoging te 
verwijderen. De grootte van de biopsie verschilde ook niet 
significant in de drie groepen en is waarschijnlijk afhankelijk 
van het borstvolume. In zeven van de 332 (2.1%) biopsieën werd 
het verdachte röntgenologische plekje niet verwijderd tijdens 
de eerste operatie. 
Aangezien drie van de zes biopsieën in tweede instantie 
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na een heroperatie toch nog een maligniteit opleverden, is de 
conclusie gewettigd dat een persisterende, röntgenologisch 
verdachte afwijking op een postoperatief controle-mammogram 
een indicatie is om opnieuw te opereren. 
Hoofdstuk II gaat over de betekenis van microcalcificaties 
zonder palpabele massa voor de diagnostiek van het mamma-
carcinoom. 
Zuivere microcalcificaties vormen een belangrijk gedeelte 
van de met-palpabele borstafwijkingen en kunnen het eerste, 
zichtbare teken van een mammacarcinoom zijn. Tussen 1975 en 
1984 werden 150 patiënten behandeld met groepjes van tenminste 
vijf microcalcificaties als enige indicatie voor mammabiopsie. 
In totaal werden 173 groepjes microcalcificaties verwijderd en 
er werden 51 maligniteiten ontdekt (29.5%). De meeste maligne 
laesies waren niet-invasief (56%). Axillaire metastasen of 
metastasen op afstand werden m 11% van de volledige evalueer-
bare gevallen gevonden. Dit wettigt de verwachting dat deze 
patiënten een zeer gunstige prognose hebben. 
Het biopteren van niet-palpabele, gegroepeerde zuivere 
microcalcificaties is een uitvoerbare en waardevolle procedure, 
waarvoor een nauwe samenwerking is vereist tussen chirurg, 
röntgendiagnost en patholoog-anatoom. 
In hoofdstuk III wordt de correlatie nagegaan tussen het 
mammografische beeld en de patholoog-anatomische diagnose van 
met-palpabele mamma-afwijkingen met in het bijzonder de 
betrouwbaarheid van het peroperatieve vriescoupe-onderzoek. 
Van de 359 biopsieën bij 321 patiënten wegens met-
palpabele, mammografische laesies bleken er 118 of 32.9% 
maligne te zijn. Ongeveer de helft van de laesies was gelocali-
seerd in het laterale bovenkwadrant. De links/rechts verhouding 
was 1.22 voor de biopsieën en 1.19 voor de occulte carcinomen. 
De 'malignancy rate' was 12.7% in geval van een circumscripte 
of nodulaire schaduw, 32.4% voor de zuivere, gegroepeerde 
microcalcificaties, 28.6% als een schaduw met microcalcificaties 
werd gezien en 66.7%, wanneer een stervormige schaduw aanwezig 
was. Er waren 76 invasieve carcinomen, waarvan 17 tubulaire 
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carcinomen. Veertig waren niet-invasieve carcinomen: 32 DCIS 
en 8 LCIS, voornamelijk behorend tot de groep van de zuivere, 
gegroepeerde microcalcificaties. Overige: twee. De gemiddelde 
leeftijd van de patiënten met invasief mammacarcinoom was 
59.8 jaar (spreiding 42-76) en bij de patiënten met niet-
invasief carcinoom 52.1 jaar (spreiding 37-68). 
De uitslagen van het vriescoupe-onderzoek werden vergeleken 
met die van de uiteindelijke paraffine-coupes en een correcte 
diagnose werd in 68.0% van de gevallen gesteld. In 17.3% werd 
geen vriescoupe-onderzoek verricht en in 12.2% werd de diagnose 
als een voorlopige afgegeven en geadviseerd de definitieve 
paraffine-coupes af te wachten. Er waren zeven fout-negatieve 
(1.9%) en twee fout-positieve (0.6%) uitslagen, beide gevallen 
van floride scleroserende adenose. Het vriescoupe-onderzoek 
is zelfs bij de niet-palpabele borstlaesies een technisch uit-
voerbare en betrouwbare methode van onderzoek gebleken op 
voorwaarde dat de patholoog-anatoom bij twijfel niet moet 
aarzelen om te adviseren de definitieve paraffine-coupes af 
te wachten. Röntgenologische controle van het biopt, hetzij 
in toto of nadat het in plakjes gesneden is, is echter in alle 
gevallen noodzakelijk. Het is waarschijnlijk verstandiij het 
vriescoupe-onderzoek niet te gebruiken voor zuivere micro-
calcif icaties en zeer kleine schaduwtjes van 5 mm of kleiner. 
Bediscussieerd wordt dat moderne mamma-sparende behandeling 
meer histologische details vergt (type tumor, andere haarden 
rond de referentie-tumor, en het al of niet tumorvrij zijn 
van de chirurgische resectieranden van het excisiebiopt of 
segmentresectiepreparaat). Het vriescoupe-onderzoek kan gewoonlijk 
niet aan deze eisen voldoen en men moet dan toch wachten op 
de definitieve paraffine-coupes en in twee tempi opereren. 
Het vóórkomen van steroidhormoonreceptoren (oestradiol-
receptor=ER en progesteronreceptor=PgR) bij het niet-palpabele 
mammacarcinoom werd nagegaan in hoofdstuk IV. 
Vier groepen patiënten, vergelijkbaar in gemiddelde 
leeftijd en menopauze-status, werden bestudeerd met betrekking 
tot hun steroidreceptorphenotype. De eerste groep bestond uit 
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patiënten met met-palpabel primair mammacarcinoom, de tweede 
groep uit palpabele en operabele primaire mammacarcinoom-
patienten, de derde groep had een locaal of regionaal reeds 
voortgeschreden primair mammacarcinoom en de vierde groep 
bestond uit patiënten ten tijde van hun eerste métastase. 
Er was een statistisch significante verschuiving in receptor-
phenotype (ER+ PgR+) van het met-palpabele mammacarcinoom 
(71%) via het palpabele en operabele primaire mammacarcinoom 
(58%) en het locaal of regionaal reeds voortgeschreden 
primaire mammacarcinoom (48%) naar het uitgezaaide mamma-
carcinoom ten tijde van de eerste métastase (41%) . 
Extrapolatie van deze gegevens geeft steun aan de theorie 
dat elk mammacarcinoom vanaf het begin van zijn ontstaan 
steroidreceptoren bevat en hormoonafhankelijk is. 
Hoofdstuk V handelt over de multicentriciteit van het met-
palpabele mammacarcinoom en de consequentie die dit heeft voor 
het therapeutisch handelen. 
Tussen 1975 en 1984 werden 100 klinisch occulte borst-
kankers ontdekt, 65 hiervan waren invasief en 35 niet-mvasief 
(27 χ DCIS en 8 χ LCIS). Drieëntachtig mastectomiepreparaten 
waren evalueerbaar met betrekking tot het vóórkomen van multi-
focaal carcinoom m een ander kwadrant van de borst of op 5 cm 
afstand van de referentie-tumor, en wat betreft resttumor 
buiten de biopsieholte. Multicentriciteit was aanwezig bij 47% 
en resttumor bij 60% van de hele groep. Als alleen de klinisch 
occulte, invasieve carcinomen werden beschouwd, dan werden 
andere haarden van invasief carcinoom aangetoond bij 26% van 
de patiënten, en achtergelaten invasief carcinoom buiten de 
biopsieholte bij 35%. Het bilateraal vóórkomen van mamma-
carcinoom in deze serie was 14%, waarvan 11% synchroon voor-
kwamen . 
Ieder therapeutisch beleid bij het niet-palpabele mamma-
carcinoom, hetzij invasief carcinoom of niet-mvasief ductaal 
carcinoom, moet gericht zijn op de hele borst. Mammografie 
van de contralaterale zijde behoort een integraal onderdeel 
te zijn van de preoperatieve voorbereiding van patiënten met 
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een palpabele laesie ipsilateraal. 
In hoofdstuk VI wordt de betekenis van het mammografisch 
onderzoek voor het ontdekken van contralateraal primair mamma-
carcinoom nagegaan aan de hand van 55 patiënten met een dubbel-
zijdig mammacarcmoom. 
Vijftien van de 23 patiënten (=65%) m de synchrone groep 
en 16 van de 32 patiënten (=50%) in de metachrone groep hadden 
een klinisch occult carcmoom in de andere borst. Wanneer 
afgezien wordt van de twee maligniteiten die ontdekt werden 
door een prophylactische mastectomie, dan was mammografie louter 
verantwoordelijk voor het ontdekken van 29 met-palpabele, 
contralaterale mammacarcinomen (=52.7%). De hele serie van 110 
borsten met maligniteit bevatte 41 met-palpabele carcinomen, 
waarvan 12 met-invasieve (7 χ DCIS en 5 χ LCIS) en de overige 
29 invasieve carcinomen, hetzij ductaal van welk type dan ook 
(25 χ) of lobulair (4 χ). Voor zover de okselklieren evalueer-
baar waren, hadden 20 van de 37 palpabele borstcarcinomen 
(=54.1%) en slechts drie van de 26 met-palpabele borstkankers 
(=11.5%) positieve klieren. De 'multicentricity rate' was 
bijzonder hoog bij synchrone tumoren (70.6%), en bij invasief 
lobulaire (=73.3%) en met-invasieve (=75%) carcinomen. 
De gunstige 5- en 10-jaars overleving van de patiënten, 
zowel met synchroon als met metachroon dubbelzijdig primair 
borstkanker, pleit ervoor deze patiënten op dezelfde manier 
te behandelen als patiënten met enkelzijdig mammacarcmoom 
en niet met pessimisme tegemoet te treden. 
En hoofdstuk VII beschrijft de behandelingsresultaten van 
met-palpabel mammacarcmoom. 
Van de 151 met-palpabele mammacarcinomen, die sedert 
1971 werden gediagnostiseerd en behandeld, waren 100 invasieve 
carcinomen, 39 DCIS en 12 LCIS. Van de 100 klinisch occulte, 
invasieve carcinomen waren er 53 met een diameter groter dan 
10 mm, 29 met een grootte van 6-10 mm, en 18 waren tumoren 
kleiner dan 5 mm. 
Bij 64.4% van de 118 volledig evalueerbare mastectomie-
preparaten werd nog resttumor buiten de excisiebiopsieholte 
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aangetroffen. Invasieve resttumor zou achtergelaten zijn bij 
34 van de 86 (39.5%) mastectomiepreparaten. 
Van 27 patiënten met in situ carcinoom was de okselstatus 
bekend en bij geen van hen werden okselkliermetastasen gevonden. 
Bi] de invasieve carcinomen echter waren okselkliermetastasen 
aanwezig m 7.7% als de primaire tumor kleiner was dan 5 mm, 
in 12.5% bi3 een grootte van 6-10 mm, en in 29.5% als de 
primaire tumor groter dan 10 mm was. 
Er was een significant betere ziekte-vnje (p<0.001) 
resp. algehele overleving (p<0.0001) bij patiënten met klinisch 
occult mammacarcinoom en negatieve okselklieren (95.7% resp. 
96.7%) dan bij patiënten met positieve okselklieren (76.0% 
resp. 72.2%). Indien de bovengrens van occult invasief carcinoom 
werd gelegd bij 10 mm, dan werden er statistisch significante 
verschillen in ziekte-vnje (p<0.01) resp. algehele overleving 
(p<0.03) gevonden tussen occult 'minimal breast cancer' 
(= niet-mvasief carcinoom + invasief carcinoom <10 mm) 
(97.7% resp. 96.9%) en occult invasief carcinoom >10 mm 
(77.3% resp. 83.6%). Echter, indien de bovengrens van occult 
invasief carcinoom werd gesteld op 5 mm, dan waren er geen 
statistisch significante verschillen (p>0.05) in ziekte-vnje 
en algehele overleving tussen occult 'minimal breast cancer' 
(= niet-mvasief carcinoom + invasief carcinoom <5 mm) en 
occult invasief carcinoom >5 mm. Ook werd er geen significant 
verschil (p>0.05) gevonden in ziekte-vri^e en algehele over-
leving tussen pre- en postmenopauzale vrouwen met occult 
mammacarcinoom. 
Concluderend kan gesteld worden dat het begrip 'minimal 
breast cancer' een zinvol begrip is, echter met dien verstande 
dat de grenzen van de oorspronkelijke definitie te nauw zijn 
en moeten worden uitgebreid, zodat naast de niet-invasieve 
tumoren, ongeacht hun grootte, ook alle invasieve tumoren 
tot en met 10 mm in grootste diameter moeten worden beschouwd 
als 'minimal breast cancers'. 
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STELLINGEN 
behorende bij het proefschrift 
SURGICAL ASPECTS OF NONPALPABLE BREAST CANCER 
J.G.M. Tinnemans 
I 
Gezien de multicentriciteit van het mammacarcinoom moet ook de 
locale behandeling van het niet-palpabele mamma-carcinoom, 
hetzij chirurgisch hetzij radiotherapeutisch, gericht zijn op 
de gehele borst (dit proefschrift). 
II 
Onder het begrip 'minimal breast cancer' dienen te vallen zowel 
alle in situ carcinomen als ook de invasieve carcinomen met een 
diameter van 10 mm of kleiner (dit proefschrift). 
III 
Mammografie van de contralaterale zijde is aangewezen bij de 
preoperatieve voorbereiding van palpabele afwijkingen ipsi-
lateraal en bij de periodieke controle van postmastectomie-
patienten (dit proefschrift). 
IV 
Er zijn aanwijzingen dat alle mammacarcinomen bij het begin 
van hun ontstaan steroidhormoon-receptoren bevatten (dit 
proefschrift). 
V 
Patienten met een Spitz-Holter drain kunnen na een stomp 
hersenletsel een ernstige intravasale stolling ontwikkelen 
ten gevolge van de drainage van hersenthromboplastines naar 
de grote circulatie (Tinnemans en Gerritsen. Intens Care Med 
1980; 6: 211-213). 
VI 
Indien bij een adolescent met een enkeltrauma op de voor-
achterwaartse röntgenfoto een fractuur Salter-Harris type III 
en op de zijdelingse röntgenfoto een fractuur Salter-Harris 
type II wordt gezien, is er sprake van een triplane (drievlaks) 
fractuur van de distale tibia epiphyse en moet er een CT-scan 
van de enkel worden gemaakt (Tinnemans en Severijnen. Injury 
1981; 12: 393-396). 
VII 
Bij ernstige comminutieve fracturen van het olecranon, waarbij 
een oefenstabiele, anatomische reconstructie niet mogelijk is, 
is excisie van de losse olecranonfragmenten en re-insertie van 
de tricepspees aan de ulna de therapie der keuze, mits de 
processus coronoideus behouden blijft (Estourgie en Tinnemans. 
Neth J Surg 1982; 34: 127-129). 
VIII 
Het laat zich aanzien dat de terescardiopexie een goede 
chirurgische techniek is ter behandeling van de symptomatische 
refluxoesophagitis. Wegens de betrekkelijke eenvoud van de 
operatie en het gebruik van lichaamseigen materiaal is een 
prospectief vergelijkend onderzoek met andere operatiemethoden 
gewenst (B. Narbona. Hernia hiatal reflujo gastroesofagico 
<terescardiopexia>. Valencia 1981). 
IX 
Voor de kleine letteren faculteiten valt te vrezen dat bij de 
huidige bezuinigingsdrift wordt vergeten dat de universiteit 
niet alleen onderwijs- en onderzoeksinstituut is, maar ook 
cultuurdrager. 
X 
De toekenning van de Nobelprijs voor literatuur aan de 
Nigeriaanse schrijver Wole Soyinka is niet alleen een teken van 
emancipatie van de zwarte neo-Afrikaanse cultuur, maar evenzeer 
van de bekronende Nobelprijscommissie die de laureaat heeft 
gezocht in een niet-westerse beschaving. 
XI 
De mens wordt verraden als hem niets meer dan de mens wordt 
geboden (Gabriel Marcel). 



